Abstract:
Disclosed are (1) a human luteinizing hormone-human chorionic gonadotropin receptor protein, (2) a DNA comprising a cDNA segment coding for a human luteinizing hormone-human chorionic gonadotropin receptor protein, (SEQ ID NO:2) (3) a transformant carrying a DNA comprising a cDNA segment (SEQ ID NO:1) coding for a human luteinizing hormone-human chorionic gonadotropin receptor protein, and (4) a method for preparing a human luteinizing hormone-human chorionic gonadotropin receptor protein which comprises cultivating the transformant described in (3), accumulating a protein (SEQ ID NO:2) in a culture broth, and collecting the same, whereby the structure and properties of the receptor protein are made clear and the mass production thereof by recombinant technology is pioneered.

Description:
BACKGROUND OF THE INVENTION 
     The present invention relates to a DNA containing a cDNA sequence coding for a human luteinizing hormone-human chorionic gonadotropin receptor protein (human LH/hCG receptor protein), the human LH/hCG receptor protein, and a method for preparing the protein. 
     The human luteinizing hormone-human chorionic gonadotropin receptor proteins (human LH/hCG receptor proteins) exist in the Leydig cells in the testis, the theca cells in the ovary, the granulosa cells, the corpus luteum cells and the interstitial cells, and play a central role in reproductive physiology. In the male and the female who is not pregnant, the LH/hCG receptor proteins are acted on only by luteinizing hormone (LH) produced in the anterior lobe of the pituitary and secreted therefrom. In the pregnant female, however, the LH/hCG receptor proteins in the ovary are acted on also by human chorionic gonadotropin (hCG) produced by the placenta. 
     LH and hCG are members of a family of glycoprotein hormones also including thyroid-stimulating hormone (TSH) and follicle-stimulating hormone (FSH). Each of these four hormones has a molecular weight of 28 to 38 kD, and is a heterodimer glycoprotein in which a specific β subunit relating to receptor binding specificity is bound to an α subunit common to these hormones. The glycosyl moiety of these hormones seem to play an important role in signal introduction. The β subunits of both LH and hCG are closely related to each other in their structure. These two hormones bind to the same receptor and induce the same biological reaction. The similarity between these glycoprotein hormones and the action by these hormones on the receptors to enhance the activity of adenylate cyclase mediated by G-proteins reveal that these receptors have a common mechanism of hormone-induced activation. The increases of adenosine 3′,5′-monophosphate (cyclic AMP) necessarily lead to the synthesis and secretion of steroids. A family of G protein-coupled receptors are identified whose members are characterized by the common structural feature of having seven transmembrane domains which are known to relate to the signal introduction and binding to small ligands. On the other hand, TSH and FSH receptors have been compared with the LH/hCG receptors. As a result, of the G protein-coupled receptors, these receptors of the pituitary glycoprotein hormones are characterized by the presence of a large glycosylated domain which is grafted onto a structure containing seven transmembrane segments and putatively considered to be positioned on the outside of cells. 
     The structure of the LH/hCG receptors have not been elucidated so well yet, because the receptors are present in very low amounts and sensitive to proteolysis. For rat and porcine LH/hCG receptors, however, complementary DNAs (cDNAs) of these receptors are isolated and the amino acid sequences thereof are also deduced from these DNAs [ Science  245, 494 (1989) for rats and  Science  245, 525 (1989) for pigs]. 
     For the rat and porcine LH/hCG receptors, the structure thereof has been thus elucidated. For the human LH/hCG receptors, however, the structure thereof is not revealed. Considering to use the human LH/hCG receptors as therapeutic drugs and analytical reagents for humans, it is necessary to make clear the structure and properties thereof. 
     SUMMARY OF THE INVENTION 
     The present inventors have recognized that important contributions will be made to future studies and medical treatments, if an human LH/hCG receptor can be collected from humans and further prepared by recombinant technology. As a result, the present inventors have first succeeded in cloning cDNA coding for a human LH/hCG receptor from a cDNA library of the human ovary by using the complementary DNA of a rat LH/hCG receptor as a probe, and in elucidating a complete nucleotide sequence thereof. Further, the present inventors have also succeeded in elucidating an amino acid sequence of the human LH/hCG receptor from this cDNA and in pioneering the mass production of this receptor by recombinant technology. This receptor is very similar to the rat and porcine receptors. However, the differences are such that each receptor can be recognized to be a different one. 
     In accordance with the present invention, there are provided (1) a human luteinizing hormone-human chorionic gonadotropin receptor protein, (2) a DNA comprising a cDNA sequence coding for a human luteinizing hormone-human chorionic gonadotropin receptor protein, (3) a transformant carrying a DNA comprising a cDNA segment coding for a human luteinizing hormone-human chorionic gonadotropin receptor protein, and (4) a method for preparing a human luteinizing hormone-human chorionic gonadotropin receptor protein which comprises culturing the transformant described in (3), accumulating a protein in a culture broth, and collecting the same. 
    
    
     BRIEF DESCRIPTION OF THE DRAWINGS 
     FIG. 1 shows a nucleotide sequence (SEQ ID NO:1) of a human LH/hCG receptor protein DNA segment, as well as an amino acid sequence (SEQ ID NO:2) deduced therefrom; and 
     FIG. 2 shows the amino acid sequence of the human LH/hCG receptor protein and amino acid sequences (SEQ ID NO:2) of other known LH/hCG receptor proteins and proteins having similar action, comparing them to one another. 
     FIGS. 3 and 4 are SDS-PAGE diagrams which show expression of HLHR protein in Example 2. 
     FIG. 5 is a graph which shows that the protein obtained according to the present invention has response ability to hCG. 
    
    
     DESCRIPTION OF THE PREFERRED EMBODIMENTS 
     The present inventors cloned two kinds of cDNAs of the human luteinizing hormone-human chorionic gonadotropin receptor protein to deduce a primary structure of the complete protein (FIG.  1 ). The first methionine in this sequence is considered to be an initiator codon. This is followed by an amino acid sequence having the characteristics of a signal peptide with a cleavage site present. A possible model for construction of the protein was suggested by hydropathy analysis and comparison with the rat and porcine LH/hCG receptors SEQ ID NO:3 and 4 respectively (FIG.  2 ). A putative extracellular domain of 335 amino acids precedes a region of 267 amino acids that displays seven possible transmembrane segments (regions surrounded by rectangles in FIG.  2  and labeled I to II). There is a 72 amino acid COOH-terminal intracellular domain. The mature protein may consist of 674 amino acids (75632 daltons). In addition to this protein, 25 signal peptides (the 1st to 25th amino acids in FIGS. 1 and 2) exist. However, these peptides are cut off during synthesis of the receptor, and therefore the mature protein of the receptor is considered to consist of 674 amino acids (the 26th to 699th amino acids, SEQ ID NO:10 is the amino acid sequence of SEQ ID NO:9). At the primary structure level, this extracellular domain has about 85% homology with the rat and porcine LH/hCG receptors and 45% homology with TSH and FSH receptors (in FIG. 2, hLH/hCGR indicates the human LH/hCG receptor; rLH/hCGR indicates the rat LH/hCG receptor; pLH/hCGR indicates the porcine LH/hCG receptor; hTSHR indicates the human TSH receptor [ Biochem. Biophys. Res. Comm . 166, 394 (1990)]; and rFSHR indicates the rat FSH receptor [ Mol. Endo . 4, 525 (1990)]). Six potential glycosylation sites are found in the putative extracellular domain (underlined portions in FIG.  1 ). Clusters of cysteine residues are present in the NH 2 -terminal portion and between the putative extracellular and transmembrane domains of the above protein. Since these cysteine residues are conserved in the LH, FSH and TSH receptors, while not wishing to be bound by theory, it may be said that the formation of disulfide bonds is crucial for the conformational integrity of the large extracellular domains of glycoprotein hormone receptors. 
     The domain considered to contain the transmembrane domains has about 90% homology with the rat and porcine LH/hCG receptors, and 70% homology with the TSH and FSH receptors. Serine and threonine residues are found with high frequency in a putative intercellular domain having three sites which is possibly phosphorylated by protein kinase C (FIG.  1 ). Since the phosphorylation by protein kinase specific to the receptors play a role in agonist specific decoupling of adrenergic receptors from the G proteins, it is important to know whether the phosphorylation in at least one of these sites causes any functional changes of the LH/hCG receptors. 
     In the present invention, in addition to a clone having a large open reading frame, a clone coding for a shorter protein was obtained. The large clone is the 1st to 699th amino acid residues (SEQ ID NO:2) in FIG. 1 (SEQ ID NO:1), and the truncated type is one from which a region of the 227th to 289th amino acid residues surrounded by a rectangle (SEQ ID NO:7) is lacking. This pattern suggests that the cleavage mechanism necessary to complete mRNA has selectivity. These results are very similar to the data of the porcine LH/hCG receptor. The role of this truncated type receptor is not understood well, and it is not known either whether this LH/hCG receptor is physiologically active as a monomer or an oligomer. In humans, this TSH receptor can be a target of autoimmune reaction which leads to hyper- or hypo-stimulation of the thyroid gland by autoantibodies in Grave&#39;s disease and idiopathic myxedema. Thus, not only for contributions to diagnosis and management of ovarian diseases, but also for better understanding of ovarian physiology, it is necessary to isolate the human LH/hCG receptor and to know its characteristics. 
     FIG. 2 shows the amino acid sequence of the novel human luteinizing hormone-human chorionic gonadotropin receptor protein (SEQ ID NO:2) obtained in the present invention, and compares this amino acid sequence with the amino acid sequences of the rat and porcine luteinizing hormone-human chorionic gonadotropin receptor proteins (SEQ ID NO:3 and 4 respectively) and the FSH and TSH receptors (SEQ ID NO:6 and 5 respectively) having similar action. The same amino acid residue as appears in the human luteinizing hormone-human chorionic gonadotropin receptor protein of the present invention, is represented by “.”, and an amino acid residue different from that of the human LH/hCG receptor is represented by the appropriate symbol as defined herein. CONSENSUS shown in FIG. 2 indicates amino acid residues common to all the glycoproteins shown in FIG.  2 . The illustration of CONSENSUS results in introduction of lacking portions “-” into the formulae in FIG.  2 . Accordingly, the number representing the amino acids is counted excluding these lacking portions. 
     For a DNA sequence, the DNA coding for the human LH/hCG receptor of the present invention contains the nucleotide sequence (SEQ ID NO:1) shown in FIG. 1 or a portion thereof. 
     As the cDNA coding for the human LH/hCG receptor of the present invention, any cDNA may be used as long as it contains a nucleotide sequence coding for an amino acid sequence of the human LH/hCG receptor. For example, DNA containing the nucleotide sequence (SEQ ID NO:1) shown in FIG. 1 or a portion thereof is preferably used. 
     The nucleotide sequence (SEQ ID NO:1) shown in FIG. 1 is an example of cDNA sequences coding for the human LH/hCG receptor obtained in the present invention. 
     In the present invention, for example, an expression vector having the cDNA containing the nucleotide sequence coding for the human LH/hCG receptor can be prepared by the following process: 
     (a) Messenger RNA (mRNA) is isolated from human LH/hCG receptor-producing cells. 
     (b) Single stranded complementary DNA (cDNA) is synthesized from the mRNA, followed by synthesis of double stranded DNA. 
     (c) The complementary DNA is introduced into a phage or a plasmid. 
     (d) Host cells are transformed with the recombinant phage or plasmid thus obtained. 
     (e) After cultivation of the transformants thus obtained, plasmids or phages containing the desired DNA are isolated from the transformants by an appropriate method such as hybridization with a DNA probe coding for a portion of the rat LH/hCG receptor or immunoassay using an anti-LH/hCG receptor antibody. 
     (f) The desired cloned DNA is cut out from the recombinant DNA. 
     (g) The cloned DNA or a portion thereof is ligated downstream from a promoter in the expression vector. 
     The mRNA coding for the human LH/hCG receptor can be obtained from various human LH/hCG receptor-producing cells, for example, germ cells such as the Leydig cells in the testis, the capsular cells in the ovary, the granulosa cells, the corpus luteum cells and the interstitial cells. 
     Methods for preparing the MRNA from the human LH/hCG receptor-producing cells include the guanidine thiocyanate method [J. M. Chirgwin et al.,  Biochemistry  18, 5294 (1979)] and the like. 
     Using the mRNA thus obtained as a template, cDNA is synthesized by use of reverse transcriptase, for example, in accordance with the method of H. Okayama et al. [ Molecular and Cellular Biology  2, 161 (1979); and  ibid . 3, 280 (1983)]. The cDNA thus obtained is introduced into the plasmid. 
     The plasmids into which the cDNA may be introduced include, for example, pBR322  [Gene  2, 95 (1977)], pBR325  [Gene  4, 121 (1978)], pUC12  [Gene  19, 259 (1982)] and pUC13  [Gene  19, 259, each derived from  Escherichia coli , and pUB110 derived from  Bacillus subtilis [Biochemical and Biophysical Research Communication  112, 678 (1983)]. However, any other plasmid can be used as long as it is replicable and viable in the host cell. Examples of the phage vectors into which the cDNA may be introduced include λgt11 [R. Young and R. Davis,  Proc. Natl. Acad. Sci. U.S.A . 80, 1194 (1983)]. However, any other phage vector can be used as long as it is viable in the host cell. 
     Methods for introducing the cDNA into the plasmid include, for example, the method described in T. Maniatis et al.,  Molecular Cloning , Cold Spring Harbor Laboratory, p.239 (1982). Methods for introducing the cDNA into the phage vector include, for example, the method of T. V. Hyunh et al. [ DNA Cloning, A Practical Approach  1, 49 (1985)]. 
     The plasmid thus obtained is introduced into an appropriate host cell such as Escherichia and Bacillus. 
     Examples of Escherichia described above include  E. coli  K12DH1  [Proc. Natl. Acad. Sci. U.S.A . 60, 160 (1968)], M103  [Nucleic Acids Research  9, 309 (1981)], JA221  [Journal of Molecular Biology  120, 517 (1978)], HB101  [Journal of Molecular Biology  41, 459 (1969)] and C600  [Genetics  39, 440 (1954)]. 
     Examples of Bacillus described above include  Bacillus subtilis  MI114  [Gene  24, 255 (1983)] and 207-21  [Journal of Biochemistry  95, 87 (1984)]. 
     Methods for transforming the host cell with the plasmid include, for example, the calcium chloride method or the calcium chloride/rubidium chloride method described in T. Maniatis et al.,  Molecular Cloning , Cold Spring harbor Laboratory, p.249 (1982). 
     When the phage vector is used, for example, it can be transduced into proliferated  E. coli , using the in vitro packaging method. 
     Human LH/hCG receptor-cDNA libraries containing human LH/hCG receptor cDNA can be purchased from the market, though obtainable by the methods described above. For example, a cDNA library of the LH/CG receptor is available from Clontech Laboratories, Inc., U.S.A. 
     Methods for cloning human LH/hCG receptor cDNA from the human DNA library include, for example, the plaque hybridization method using phage vector λcharon 28A and rat LH/hCG receptor cDNA as a probe [T. Maniatis et al.,  Molecular Cloning , Cold Spring Harbor Laboratory, (1982)]. 
     The human LH/hCG receptor cDNA thus cloned may be subcloned, for example, in pBR322, pUC12, pUC13, pUC18, pUC19, pUC118 and pUC119 to obtain the human LH/hCG receptor cDNA, if necessary. 
     The nucleotide sequence of the cDNA thus obtained is determined, for example, by the Maxam-Gilbert method [A. M. Maxam and W. Gilbert,  Proc. Natl. Acad. Sci. U.S.A . 74, 560 (1977)] or the dideoxy method [J. Messing et al.,  Nucleic Acids Research  9, 309 (1981)], and the existence of the human LH/hCG receptor cDNA is confirmed in comparison with the known amino acid sequence. 
     As described above, the cDNA coding for the human LH/hCG receptor protein is obtained. 
     FIG. 1 shows the nucleotide sequence of the cDNA (SEQ ID NO:1) determined by the dideoxy method for the cDNA coding for the human LH/hCG receptor protein obtained in Example 1 described below, and the amino acid sequence proved from that nucleotide sequence. 
     The cDNA coding for the human LH/hCG.receptor protein (SEQ ID NO:2) cloned as described above can be used as is, or after digestion with a restriction enzyme if desired, depending on the intended use. 
     A region intended to be expressed is cut out from the cloned cDNA and ligated downstream from a promoter in a vehicle (vector) suitable for expression, whereby the expression vector can be obtained. 
     The cDNA has ATG as a translation initiating codon at the 5′-terminus thereof and may have TAA, TGA or TAG as a translation terminating codon at the 3′-terminus. The translation initiating codon and translation terminating codon may be added by use of an appropriate synthetic cDNA adaptor. A promoter is further ligated upstream therefrom for the purpose of expressing the cDNA. 
     Examples of the vectors include the above plasmids derived from  E. coli  such as pBR322, pBR325, pUC12 and pUC13, the plasmids derived from  Bacillus subtilis  such as pUB110, pTP5 and pC194, plasmids derived from yeast such as pSH19 and pSH15, bacteriophages such as λ phage, and animal viruses such as retroviruses and vaccinia viruses. 
     As the promoter used in the present invention, any promoter is available as long as it is suitable for expression in the host cell selected for the gene expression. 
     When the host cell used for transformation is Escherichia, it is preferable that a trp promoter, a lac promoter, a recA promoter, a λP L  promoter, a lpp promoter, etc. are used. When the host cell is Bacillus, it is preferable that a SPO1 promoter, a SPO2 promoter, a penp promoter, etc. are used. When the host cell is yeast, it is preferable that a PHO5 promoter, a PGK promoter, a GAP promoter, an ADH promoter, etc. are used. In particular, it is preferable that the host cell is Escherichia and the promoter is the trp promoter or the λP L  promoter. 
     When the host cell is an animal cell, a SV-40 derived promoter, a retrovirus promoter, a metallothionein promoter, a heat shock promoter, etc. are each usable. 
     An enhancer is also effectively used for expression. 
     Using a vector containing the cDNA coding for the mature peptide of the human LH/hCG receptor protein thus constructed, transformants are prepared. 
     The host cells include, for example, Escherichia, Bacillus, yeast and animal cells. 
     Specific examples of the above Escherichia and Bacillus include strains similar to those described above. 
     Examples of the above yeast include  Saccharomyces cerevisiae  AH22, AH22R − , NA87-11A and DKD-5D. 
     Examples of the animal cells include monkey cell COS-7, Vero, Chinese hamster cell (CHO), mouse L cell and human FL cell. 
     The transformation of the above Escherichia is carried out, for example, according to the method described in  Proc. Natl. Acad. Sci. U.S.A . 69, 2110 (1972) or  Gene  17, 107 (1982). 
     The transformation of the above Bacillus is conducted, for example, according to the method described in  Molecular &amp; General Genetics  168, 111 (1979). 
     The transformation of the yeast is carried out, for example, according to the method described in  Proc. Natl. Acad. Sci. U.S.A . 75, 1929 (1978). 
     The transformation of the animal cells is carried out, for example, according to the method described in  Virology  52, 456 (1973). 
     Thus, transformants are obtained which have been transformed with the expression vector containing the cDNA coding for the human LH/hCG receptor. 
     When bacterial transformants are cultured, a liquid medium is particularly suitable as a medium used for culture. Carbon sources, nitrogen sources, inorganic compounds and others necessary for growth of the transformants are contained therein. Examples of the carbon sources include glucose, dextrin, soluble starch and sucrose. Examples of the nitrogen sources include inorganic or organic materials such as ammonium salts, nitrates, corn steep liquor, peptone, casein, meat extracts, soybean meal and potato extract solution. The inorganic compounds include, for example, calcium chloride, sodium dihydrogenphosphate and magnesium chloride. Yeast, vitamins, growth promoting factors and so on may be further added thereto. 
     The pH of the medium is preferably about 5 to 8. 
     As the medium used for cultivation of Escherichia, for example, M9 medium containing glucose and Casamino Acids (Miller,  Journal of Experiments in Molecular Genetics  431-433, Cold Spring Harbor Laboratory, New York, 1972) is preferably used. In order to make the promoter act efficiently, a drug such as 3-β-indolylacrylic acid may be added thereto if necessary. 
     When the host cell is Escherichia, the cultivation is usually carried out at about 15 to 43° C. for about 3 to 24 hours, with aeration or agitation if necessary. 
     When the host cell is Bacillus, the cultivation is usually carried out at about 30 to 40° C. for about 6 to 24 hours, with aeration or agitation if necessary. 
     When yeast transformants are cultured, for example, Burkholder minimum medium [K. L. Bostian et al.,  Proc. Natl. Acad. Sci. U.S.A . 77, 4505 (1980)] is used as the medium. The pH of the medium is preferably adjusted to about 5 to 8. The cultivation is usually carried out at about 20 to 35° C. for about 24 to 72 hours, with aeration or agitation if necessary. 
     When animal cell transformants are cultured, examples of the mediums include MEM medium containing about 5 to 20% fetal calf serum [ Science  122, 501 (1952)], DMEM medium [ Virology  8, 396 (1959)], RPMI1640 medium ( The Journal of the American Medical Association  199, 519 (1967)] and 199 medium [ Proceeding of the Society for the Biological Medicine  73, 1 (1950). The pH is preferably about 6 to 8. The cultivation is usually carried out at about 30 to 40° C. for about 15 to 60 hours, with aeration or agitation if necessary. 
     The human LH/hCG receptor protein can be isolated and purified from the culture described above, for example, by the following method. 
     When the human LH/hCG receptor protein is extracted from the cultured cells, the cells are collected by methods known in the art after cultivation. Then, the collected cells are suspended in an appropriate buffer solution and disrupted by ultrasonic treatment, lysozyme and/or freeze-thawing. Thereafter, a crude extracted solution of the human LH/hCG receptor mature peptide is obtained by centrifugation or filtration. The buffer solution may contain a protein denaturant such as urea or guanidine hydrochloride, or a surface-active agent such as Triton X-100. 
     When the human LH/hCG receptor protein is secreted in the culture solution, a supernatant is separated from the cells by methods known in the art after the conclusion of cultivation, and then collected. 
     The separation and purification of the human LH/hCG receptor contained in the culture supernatant or the extracted solution thus obtained can be performed by an appropriate combination of known separating and purifying methods. The known separating and purifying methods include methods utilizing solubility such as salt precipitation and solvent precipitation, methods mainly utilizing a difference in molecular weight such as dialysis, ultrafiltration, gel filtration and SDS-polyacrylamide gel electrophoresis, methods utilizing a difference in electric charge such as ion-exchange column chromatography, methods utilizing specific affinity such as affinity chromatography, methods utilizing a difference in hydrophobicity such as reverse phase high performance liquid chromatography and methods utilizing a difference in isoelectric point such as isoelectro-focussing electrophoresis. A method may also be used in which an antibody to a fused protein expressed by fusing the human LH/hCG receptor complimentary DNA together with  E. coli -derived DNA lacZ is used as an immunoaffinity column. 
     The activity of the human LH/hCG receptor protein thus formed can be measured by an enzyme immunoassay using a specific antibody. 
     The cells transfected or transformed with the cDNA of the present invention can allow the human LH/hCG receptor protein to be produced in large amounts. 
     The human LH/hCG receptor protein produced here is channeled into the study of ovarian physiology, the supply of antibodies to the receptor, the diagnosis and management of ovarian or testicular diseases such as ovulation aberration or oligospermia, and the development of contraceptives. In humans, this TSH receptor can be a target of autoimmune reaction which leads to hyper- or hypo-stimulation of the thyroid gland by autoantibodies in Grave&#39;s disease and idiopathic myxedema. The LH/hCG receptor might therefore suppress the LH action in vivo or can conduct hyperstimulation in stead of LH to cause morbidity in the human genital system. The anti-receptor antibody can be detected by producing the receptor by any of the above-described methods, labeling it and examining whether one binding to it (antibody) is present in vivo or not. In addition, it is considered that inhibition of the LH action by an antibody obtained by expressing a portion or all of the receptor cDNA, namely the application of the antibody as a contraceptive, is possible. 
     There have been described above in detail the cloning of the cDNA coding for the human LH/hCG receptor protein, the preparation of the expression vectors for the human LH/hCG receptor protein, the production of the transformants thereby, the production of the human LH/hCG receptor protein by using the transformants and utility thereof. 
     When nucleotides, amino acids and so on are indicated by abbreviations in this specification and drawings, the abbreviations adopted by the IUPAC-IUB Commission on Biochemical Nomenclature or commonly used in the art are employed. For example, the following abbreviations are used. When the amino acids are capable of existing as optical isomers, it is understood that the L-forms are represented unless otherwise specified. 
     DNA: Deoxyribonucleic acid 
     cDNA: Complementary deoxyribonucleic acid 
     A: Adenine 
     T: Thymine 
     G: Guanine 
     C: Cytosine 
     RNA: Ribonucleic acid 
     mRNA: Messenger ribonucleic acid 
     dATP: Deoxyadenosine triphosphate 
     dTTP: Deoxythymidine triphosphate 
     dGTP: Deoxyguanosine triphosphate 
     dCTP: Deoxycytidine triphosphate 
     ATP: Adenosine triphosphate 
     EDTA: Ethylenediaminetetraacetic acid 
     SDS: Sodium dodecyl sulfate 
     Gly or G: Glycine 
     Ala or A: Alanine 
     Val or V: Valine 
     Leu or L: Leucine 
     Ile or I: Isoleucine 
     Ser or S: Serine 
     Thr or T: Threonine 
     Cys or C: Cysteine 
     Met or M: Methionine 
     Glu or E: Glutamic acid 
     Asp or D: Aspartic acid 
     Lys or K: Lysine 
     Arg or R: Arginine 
     His or H: Histidine 
     Phe or F: Phenylalanine 
     Tyr or Y: Tyrosine 
     Trp or W: Tryptophan 
     Pro or P: Proline 
     Asn or N: Asparagine 
     Gln or Q: Glutamine 
     The precise chemical structure of the human luteinizing hormone-human chorionic gonadotropin receptor proteins of the present invention will depend on a number of factors. Because ionizable amino and carboxyl groups are present in these proteins, a particular protein may be obtained as an acidic or basic salt, or in neutral form. All such preparations which retain their bioactivity when placed in suitable environmental conditions are included in the definition of the receptor proteins of the present invention. Further, the primary amino acid sequence of such proteins may be argumented by derivation using sugar moieties or by other supplementary molecules such as lipids, phosphate, acetyl groups and the like. Such modifications are included in the definition of the receptor proteins of the present invention so long as the bioactivity of the protein is not destroyed. It is expected, of course, that such modifications may quantitatively or qualitatively affect the bioactivity by either enhancing or diminishing the activity of the protein. 
     Further, individual amino acid residues in the chain may be modified by oxidation, reduction, or other derivatization, and the receptor proteins of the present invention may be cleaved to obtain fragments which retain bioactivity. Such alterations which do not destroy bioactivity do not remove such receptor proteins from the definition. 
     Finally modifications to the primary structure itself by deletion, addition, or alteration of the amino acids incorporated into the sequence during translation can be made without destroying the activity of the receptor proteins of the present invention. 
     The present invention will hereinafter be described in more detail with the following Examples. It is understood of course that these Examples are not intended to limit the scope of the invention. 
     Transformant  E. coli  JM109/pUC18 obtained in Example 1 described below was deposited with the Fermentation Research Institute, the Agency of Industrial Science and Technology, the Ministry of International Trade and Industry, Japan (FRI) under the accession number FERM BP-3127 on Oct. 9, 1990. This microorganism was deposited with the Institute for Fermentation, Osaka, Japan (IFO) under the accession number IFO 15096 on Oct. 11, 1990. 
     Transformants  E. coli  DH1/pHLHR(UEX2) and  E. coli  JM109pHLHR(GEX-3X) obtained in Example 2 described below were deposited with the Fermentation Research Institute, the Agency of Industrial Science and Technology, the Ministry of International Trade and Industry, Japan (FRI) under the accession number FERM BP-3545 and FERM BP-3544 respectively on Aug. 29, 1991. 
     EXAMPLE 1 
     (1) Preparation of a Human Ovary-Derived cDNA Library 
     Total RNA was extracted from the human ovary by the guanidine thiocyanate method, and then mRNA was purified by use of an oligo(dt) cellulose column (Type 7, Pharmacia). Using a cDNA synthesizing kit (Pharmacia), cDNA was synthesized from about 2 μg of purified mRNA. The terminus of this cDNA was rendered flush with T4 DNA polymerase, followed by addition of an EcoRI adapter. This cDNA was bound to a λgt10 vector, and in vitro packaging was carried out by use of a packaging kit (Gigapack Gold, Stratagene). This library contained 1×10 6  independent recombinants, and was proliferated. 
     (2) Purification of a Probe 
     A cDNA library was prepared from the rat ovary in a manner similar to that described above, and inserted into a λZaPII vector (Stratagene). A rat LH/hCG receptor was cloned therefrom to isolate clones Zap3-5-1 (2.8 kb). The clones were labeled using the random primer method (Amersham), and used as a probe. 
     (3) Screening 
     A λgt10 cDNA library phage solution of 5×10 4  plaque forming units (pfu) was mixed with 500 μl of C600hfl (cultivated overnight), and the mixture was incubated at 37° C. for 15 minutes. Then, 8 ml of 0.75% agarose (Nippon Gene) LB was added thereto, and the mixture was inoculated on a 1.5% agar LB plate (15 cm dish). A nitrocellulose filter (Hybond-N, Amersham) was placed on the plate on which plaques were formed, and DNA was fixed. Subsequently, the filter was prehybridized at 65° C. for 1 to 2 hours in a solution prepared by adding 0.1% bovine serum albumin (BSA), polyvinylpyrrolidone, Ficoll 400 (Pharmacia), 5% pyrophosphoric acid and 0.1% SDS to 6×SSC (0.15 M NaCl, 0.015 M sodium citrate, pH 7.0). On hybridization, the probe was added to 200,000 cpm/ml as a guide. The filter was washed with 6×SSC at 42° C. for 15 minutes, and subsequently with 0.1×SSC at 65° C. for 10 minutes. Then, the filter was subjected to autoradiography at −70° C. 
     (4) Analysis of DNA Sequence 
     Some clones were identified, and the longest was selected from these clones for sequence analysis. This clone was subcloned into pUC18 (Takara), and  E. coli  JM109 was transformed with the resulting plasmid to yield transformant  E. coli  JM109/pUC18 (FERM BP-3127). This transformant was further shaved off stepwise by exonuclease digestion to prepare long to short single stranded DNA fragments. Sequence analysis was carried out by the dideoxy chain terminal method using a 7DEAZA sequencing kit. Electrophoresis was carried out by use of a LKB2010 Macrophor sequencing system. The SDC Genetyx software was used for data analysis. 
     FIG. 1 shows the nucleotide sequence (SEQ ID NO:1) of the DNA of the human LH/hCG receptor protein, as well as the amino acid sequence deduced therefrom. The nucleotide sequence obtained in the present invention has additional 8 DNAs (−8 to −1) prior to N-terminus of the nucleotide sequence of SEQ ID NO:1. 
     EXAMPLE 2 
     Expression of Human LH/HCG Receptor Protein (sometimes referred to herein as HLHR protein) 
     (1) The HLHR cDNA clones obtained in Example 1 were used. The lac Z-HLHR fusion gene was obtained by cloning the 1400 bp EcoRI-Xba fragment coding for extracellular segment of the HLHR into the BamHI site of pUEX2. The lac Z-HLHR fusion construction was transformed into  E. coli  DH1 host to yield transformant  E. coli  DH1/pHLHR(UEX2) (FERM BP-3545). 
     For preparation of lacZ-HLHR fusion protein, the transformant was cultivated in LB overnight at 30° C. 5 ml of the LB medium was innoculated with 50 μl of the overnight culture. After incubation of 2 hr at 30° C. with aeration and further incubation of 2 hr at 42° C., the cells were pelleted. 
     The pellets were dissolved in a SDS-polyacrylamide gel electrophoresis (PAGE) sample buffer. The solution was subjected to 5% SDS-PAGE.  E. coli  transformed with pUEX2 vector was similarlly subjected to 5% SDS-PAGE. After electrophoresis, the gel was stained with Coomassie Blue. The result is shown in FIG.  3 . Lane 1 shows a molecular weight marker, lane 2 shows the case of pUEX2 vector and lane 3 shows the present transformant. A band at 110 kda of lane 2 disappears and a new band at 159 kda appears. The result of the electrophoresis and analysis of the nucleotide sequence show the expression of HLHR protein. 
     (2) The GST (glutathion S-transferase) -HLHR fusion gene was obtained by cloning the 1400 bp EcoRI-Xba fragment coding for extracellular segment of the HLHR into the BamHI site of pGEX-3X(Pharmacia). The GST-HLHR fusion construction was transformed into  E. coli  JM 109 host to yield  E. coli  JM109/pHLHR(GEX-3X) (FERM BP-3544). The transformant was cultivated in LB overnight at 30° C. The overnight culture of JM 109 was diluted 1:10 in 500 ml of fresh medium and cultivated for 1 hr at 37° C. before adding IPTG to 0.1 mM. After further 7 hr culture, the cells were pelleted. 
     The pellets were dissolved in a SDS-polyacrylamide gel electrophoresis (PAGE) sample buffer. The solution was subjected to 10% SDS-PAGE.  E. coli  transformed with pGEX-3X vector was similarily subjected to 10% SDS-PAGE. After electrophoresis, the gel was stained with Coomassie Blue. The result is shown in FIG.  4 . Lane 1 shows a molecular weight marker, lane 2 shows the case of pGEX-3X vector and lane 3 shows the present transformant. A band at 26 kda of lane 2 disappears and a new band at 75 kda appears. The result of the electrophoresis and analysis of the nucleotide sequence show the expression of HLHR protein. 
     (3) Functional Expression of HLHR 
     The expression vector pCHLHR was constructed by introducing the entire coding region of the cloned cDNA and additional flunking regions contained on an RcoRI fragment (2995 bp) into the pCDNA 1 vector. Human kidney 293 cells (ATCC CRL 1573) were maintained in Dulbecco&#39;s modified Eagle&#39;s medium containing 10% Fetal Calf serum in a humidified atmosphere containing 5% CO 2 . These cells were transiently transfected with PCHLHR, an expression vector encoding for the full-length human LH/hCG receptor, according to the procedure of calcium phosphate-mediated transfection. These cells were tested for their response ability to hCG with an increase in cAMP levels. The result is shown in FIG.  5 . In FIG. 5, the points indicate the mean and the bars indicate the range of the data. 
     The present invention has been described in detail, including the preferred embodiments thereof. However, it will be appreciated that those skilled in the art, upon consideration of the present disclosure, may make modifications and improvements on this invention and still be within the scope and spirit of this invention as set forth in the following claims. 
     
       
         
           
             10 
           
           
             
               2987 base pairs 
               nucleic acid 
               double 
               linear 
             
             
               cDNA to mRNA 
             
             
               unknown 
             
             
               CDS 
                1..2097 
             
              1
ATG AAG CAG CGG TTC TCG GCG CTG CAG CTG CTG AAG CTG CTG CTG CTG       48
Met Lys Gln Arg Phe Ser Ala Leu Gln Leu Leu Lys Leu Leu Leu Leu
  1               5                  10                  15
CTG CAG CCG CCG CTG CCA CGA GCG CTG CGC GAG GCG CTC TGC CCT GAG       96
Leu Gln Pro Pro Leu Pro Arg Ala Leu Arg Glu Ala Leu Cys Pro Glu
             20                  25                  30
CCC TGC AAC TGC GTG CCC GAC GGC GCC CTG CGC TGC CCC GGC CCC ACG      144
Pro Cys Asn Cys Val Pro Asp Gly Ala Leu Arg Cys Pro Gly Pro Thr
         35                  40                  45
GCC GGT CTC ACT CGA CTA TCA CTT GCC TAC CTC CCT GTC AAA GTG ATC      192
Ala Gly Leu Thr Arg Leu Ser Leu Ala Tyr Leu Pro Val Lys Val Ile
     50                  55                  60
CCA TCT CAA GCT TTC AGA GGA CTT AAT GAG GTC ATA AAA ATT GAA ATC      240
Pro Ser Gln Ala Phe Arg Gly Leu Asn Glu Val Ile Lys Ile Glu Ile
 65                  70                  75                  80
TCT CAG ATT GAT TCC CTG GAA AGG ATA GAA GCT AAT GCC TTT GAC AAC      288
Ser Gln Ile Asp Ser Leu Glu Arg Ile Glu Ala Asn Ala Phe Asp Asn
                 85                  90                  95
CTC CTC AAT TTG TCT GAA ATA CTG ATC CAG AAC ACC AAA AAT CTG AGA      336
Leu Leu Asn Leu Ser Glu Ile Leu Ile Gln Asn Thr Lys Asn Leu Arg
            100                 105                 110
TAC ATT GAG CCC GGA GCA TTT ATA AAT CTT CCC GGA TTA AAA TAC TTG      384
Tyr Ile Glu Pro Gly Ala Phe Ile Asn Leu Pro Gly Leu Lys Tyr Leu
        115                 120                 125
AGC ATC TGT AAC ACA GGC ATC AGA AAG TTT CCA GAT GTT ACG AAG GTC      432
Ser Ile Cys Asn Thr Gly Ile Arg Lys Phe Pro Asp Val Thr Lys Val
    130                 135                 140
TTC TCC TCT GAA TCA AAT TTC ATT CTG GAA ATT TGT GAT AAC TTA CAC      480
Phe Ser Ser Glu Ser Asn Phe Ile Leu Glu Ile Cys Asp Asn Leu His
145                 150                 155                 160
ATA ACC ACC ATA CCA GGA AAT GCT TTT CAA GGG ATG AAT AAT GAA TCT      528
Ile Thr Thr Ile Pro Gly Asn Ala Phe Gln Gly Met Asn Asn Glu Ser
                165                 170                 175
GTA ACA CTC AAA CTA TAT GGA AAT GGA TTT GAA GAA GTA CAA AGT CAT      576
Val Thr Leu Lys Leu Tyr Gly Asn Gly Phe Glu Glu Val Gln Ser His
            180                 185                 190
GCA TTC AAT GGG ACG ACA CTG ACT TCA CTG GAG CTA AAG GAA AAC GTA      624
Ala Phe Asn Gly Thr Thr Leu Thr Ser Leu Glu Leu Lys Glu Asn Val
        195                 200                 205
CAT CTG GAG AAG ATG CAC AAT GGA GCC TTC CGT GGG GCC ACA GGG CCG      672
His Leu Glu Lys Met His Asn Gly Ala Phe Arg Gly Ala Thr Gly Pro
    210                 215                 220
AAA ACC TTG GAT ATT TCT TCC ACC AAA TTG CAG GCC CTG CCG AGC TAT      720
Lys Thr Leu Asp Ile Ser Ser Thr Lys Leu Gln Ala Leu Pro Ser Tyr
225                 230                 235                 240
GGC CTA GAG TCC ATT CAG AGG CTA ATT GCC ACG TCA TCC TAT TCT CTA      768
Gly Leu Glu Ser Ile Gln Arg Leu Ile Ala Thr Ser Ser Tyr Ser Leu
                245                 250                 255
AAA AAA TTG CCA TCA AGA GAA ACA TTT GTC AAT CTC CTG GAG GCC ACG      816
Lys Lys Leu Pro Ser Arg Glu Thr Phe Val Asn Leu Leu Glu Ala Thr
            260                 265                 270
TTG ACT TAC CCC AGC CAC TGC TGT GCT TTT AGA AAC TTG CCA ACA AAA      864
Leu Thr Tyr Pro Ser His Cys Cys Ala Phe Arg Asn Leu Pro Thr Lys
        275                 280                 285
GAA CAG AAT TTT TCA CAT TCC ATT TCT GAA AAC TTT TCC AAA CAA TGT      912
Glu Gln Asn Phe Ser His Ser Ile Ser Glu Asn Phe Ser Lys Gln Cys
    290                 295                 300
GAA AGC ACA GTA AGG AAA GTG AGT AAC AAA ACA CTT TAT TCT TCC ATG      960
Glu Ser Thr Val Arg Lys Val Ser Asn Lys Thr Leu Tyr Ser Ser Met
305                 310                 315                 320
CTT GCT GAG AGT GAA CTG AGT GGC TGG GAC TAT GAA TAT GGT TTC TGC     1008
Leu Ala Glu Ser Glu Leu Ser Gly Trp Asp Tyr Glu Tyr Gly Phe Cys
                325                 330                 335
TTA CCC AAG ACA CCC CGA TGT GCT CCT GAA CCA GAT GCT TTT AAT CCC     1056
Leu Pro Lys Thr Pro Arg Cys Ala Pro Glu Pro Asp Ala Phe Asn Pro
            340                 345                 350
TGT GAA GAC ATT ATG GGC TAT GAC TTC CTT AGG GTC CTG ATT TGG CTG     1104
Cys Glu Asp Ile Met Gly Tyr Asp Phe Leu Arg Val Leu Ile Trp Leu
        355                 360                 365
ATT AAT ATT CTA GCC ATC ATG GGA AAC ATG ACT GTT CTT TTT GTT CTC     1152
Ile Asn Ile Leu Ala Ile Met Gly Asn Met Thr Val Leu Phe Val Leu
    370                 375                 380
CTG ACA AGT CGT TAC AAA CTT ACA GTG CCT CGT TTT CTC ATG TGC AAT     1200
Leu Thr Ser Arg Tyr Lys Leu Thr Val Pro Arg Phe Leu Met Cys Asn
385                 390                 395                 400
CTC TCC TTT GCA GAC TTT TGC ATG GGG CTC TAT CTG CTG CTC ATA GCC     1248
Leu Ser Phe Ala Asp Phe Cys Met Gly Leu Tyr Leu Leu Leu Ile Ala
                405                 410                 415
TCA GTT GAT TCC CAA ACC AAG GGC CAG TAC TAT AAC CAT GCC ATA GAC     1296
Ser Val Asp Ser Gln Thr Lys Gly Gln Tyr Tyr Asn His Ala Ile Asp
            420                 425                 430
TGG CAG ACA GGG AGT GGG TGC AGC ACT GCT GGC TTT TTC ACT GTA TTC     1344
Trp Gln Thr Gly Ser Gly Cys Ser Thr Ala Gly Phe Phe Thr Val Phe
        435                 440                 445
GCA AGT GAA CTT TCT GTC TAC ACC CTC ACC GTC ATC ACT CTA GAA AGA     1392
Ala Ser Glu Leu Ser Val Tyr Thr Leu Thr Val Ile Thr Leu Glu Arg
    450                 455                 460
TGG CAC ACC ATC ACC TAT GCT ATT CAC CTG GAC CAA AAG CTG CGA TTA     1440
Trp His Thr Ile Thr Tyr Ala Ile His Leu Asp Gln Lys Leu Arg Leu
465                 470                 475                 480
AGA CAT GCC ATT CTG ATT ATG CTT GGA GGA TGG CTC TTT TCT TCT CTA     1488
Arg His Ala Ile Leu Ile Met Leu Gly Gly Trp Leu Phe Ser Ser Leu
                485                 490                 495
ATT GCT ATG TTG CCC CTT GTC GGT GTC AGC AAT TAC ATG AAG GTC AGT     1536
Ile Ala Met Leu Pro Leu Val Gly Val Ser Asn Tyr Met Lys Val Ser
            500                 505                 510
ATT TGC TTC CCC ATG GAT GTG GAA ACC ACT CTC TCA CAA GTC TAT ATA     1584
Ile Cys Phe Pro Met Asp Val Glu Thr Thr Leu Ser Gln Val Tyr Ile
        515                 520                 525
TTA ACC ATC CTG ATT CTC AAT GTG GTG GCC TTC TTC ATA ATT TGT GCT     1632
Leu Thr Ile Leu Ile Leu Asn Val Val Ala Phe Phe Ile Ile Cys Ala
    530                 535                 540
TGC TAC ATT AAA ATT TAT TTT GCA GTT CGA AAC CCA GAA TTA ATG GCT     1680
Cys Tyr Ile Lys Ile Tyr Phe Ala Val Arg Asn Pro Glu Leu Met Ala
545                 550                 555                 560
ACC AAT AAA GAT ACA AAG ATT GCT AAG AAA ATG GCA ATC CTC ATC TTC     1728
Thr Asn Lys Asp Thr Lys Ile Ala Lys Lys Met Ala Ile Leu Ile Phe
                565                 570                 575
ACC GAT TTC ACC TGC ATG GCA CCT ATC TCT TTT TTT GCC ATC TCA GCT     1776
Thr Asp Phe Thr Cys Met Ala Pro Ile Ser Phe Phe Ala Ile Ser Ala
            580                 585                 590
GCC TTC AAA GTA CCT CTT ATC ACA GTA ACC AAC TCT AAA GTT TTA CTG     1824
Ala Phe Lys Val Pro Leu Ile Thr Val Thr Asn Ser Lys Val Leu Leu
        595                 600                 605
GTT CTT TTT TAT CCC ATC AAT TCT TGT GCC AAT CCA TTT CTG TAT GCA     1872
Val Leu Phe Tyr Pro Ile Asn Ser Cys Ala Asn Pro Phe Leu Tyr Ala
    610                 615                 620
ATA TTC ACT AAG ACA TTC CAA AGA GAT TTC TTT CTT TTG CTG AGC AAA     1920
Ile Phe Thr Lys Thr Phe Gln Arg Asp Phe Phe Leu Leu Leu Ser Lys
625                 630                 635                 640
TTT GGC TGC TGT AAA CGT CGG GCT GAA CTT TAT AGA AGG AAA GAT TTT     1968
Phe Gly Cys Cys Lys Arg Arg Ala Glu Leu Tyr Arg Arg Lys Asp Phe
                645                 650                 655
TCA GCT TAC ACC TCC AAC TGC AAA AAT GGC TTC ACT GGA TCA AAT AAG     2016
Ser Ala Tyr Thr Ser Asn Cys Lys Asn Gly Phe Thr Gly Ser Asn Lys
            660                 665                 670
CCT TCT CAA TCC ACC TTG AAG TTG TCC ACA TTG CAC TGT CAA GGT ACA     2064
Pro Ser Gln Ser Thr Leu Lys Leu Ser Thr Leu His Cys Gln Gly Thr
        675                 680                 685
GCT CTC CTA GAC AAG ACT CGC TAC ACA GAG TGT TAACTGTTAC ATCAGTAA     2117
Ala Leu Leu Asp Lys Thr Arg Tyr Thr Glu Cys
    690                 695
GCATTATTGA ATTGTTCTTA AACCTGTAAA AAAAAATTAC CTGTACCAGT AATTTTAACA   2177
TAAAGGGTTG GATTTAGGAA ATTATTTATT TTTAGGTACA TTAGGCAAGA GACCTCTACC   2237
TAGTAGAAAG TGTAGTCTAT GACCACTGCC ACACGTAAAA ACTATTTGTC ATTGTTACAT   2297
GGCATAAATA TGAAGTTGAG AGTGTTTAGA AATTTTTATA GAAATTTTGA CACAGTAATT   2357
TTGTTTGATG AATCTTTTAA AAAACAGAGG AGGTATTTTG CATATCTTTT TTTCATTTTC   2417
GTAATTTGTA TTGCATTCTA TAAAAATATT AGTTCATAAC AGATCAGAAA TTTAAAATAA   2477
GGGGCTTTTT CCTCAGGTAG TTTGAAAAAC ACACTCTAGA GATGCACTGT TCAATTCGGT   2537
ACGCACTAGC CACATGTGGC TAAATTAAAA TTAAATAAAA TGAGAAATGT AGTTTCTCAG   2597
TTGCACTACG TTTCAAGTTC TCAATGGCTA CGTCAAGTTC TCAATGGCTA CGTGTGACTA   2657
GTGCTTACCA TACTGGACAG CACAGACACA GAATATTTTC ATCACCACAG AAAGTTCTAT   2717
CTGTTCTATT ATAGAGACTT TTATGTATGC CCTATCTGGA TTCTACTTAT TTATAATTTA   2777
AGGTAAACAT CTGAAAGCAC ATTTCAGCCT ATTTGCTTAG TGAAACATTA AGCTGTAGAC   2837
TGTAAACTCC TCGTGAGTAG GAACCCTGTC TCAGTGCATT TTGTTTTCCT GCTTCCTACC   2897
TCAAGATCTT GGCAATGGTA CACTACAAAT GTGCTGAGTT AGAATTACTC TGAAGTTATG   2957
AAACATATAA TGAAAACAAT TTTTCCGGCC                                    2987 
           
           
             
               699 amino acids 
               amino acid 
               linear 
             
             
               protein 
             
             
               unknown 
             
              2
Met Lys Gln Arg Phe Ser Ala Leu Gln Leu Leu Lys Leu Leu Leu Leu
  1               5                  10                  15
Leu Gln Pro Pro Leu Pro Arg Ala Leu Arg Glu Ala Leu Cys Pro Glu
             20                  25                  30
Pro Cys Asn Cys Val Pro Asp Gly Ala Leu Arg Cys Pro Gly Pro Thr
         35                  40                  45
Ala Gly Leu Thr Arg Leu Ser Leu Ala Tyr Leu Pro Val Lys Val Ile
     50                  55                  60
Pro Ser Gln Ala Phe Arg Gly Leu Asn Glu Val Ile Lys Ile Glu Ile
 65                  70                  75                 80
Ser Gln Ile Asp Ser Leu Glu Arg Ile Glu Ala Asn Ala Phe Asp Asn
                 85                  90                  95
Leu Leu Asn Leu Ser Glu Ile Leu Ile Gln Asn Thr Lys Asn Leu Arg
            100                 105                 110
Tyr Ile Glu Pro Gly Ala Phe Ile Asn Leu Pro Gly Leu Lys Tyr Leu
        115                 120                 125
Ser Ile Cys Asn Thr Gly Ile Arg Lys Phe Pro Asp Val Thr Lys Val
    130                 135                 140
Phe Ser Ser Glu Ser Asn Phe Ile Leu Glu Ile Cys Asp Asn Leu His
145                 150                 155                 160
Ile Thr Thr Ile Pro Gly Asn Ala Phe Gln Gly Met Asn Asn Glu Ser
                165                 170                 175
Val Thr Leu Lys Leu Tyr Gly Asn Gly Phe Glu Glu Val Gln Ser His
            180                 185                 190
Ala Phe Asn Gly Thr Thr Leu Thr Ser Leu Glu Leu Lys Glu Asn Val
        195                 200                 205
His Leu Glu Lys Met His Asn Gly Ala Phe Arg Gly Ala Thr Gly Pro
    210                 215                 220
Lys Thr Leu Asp Ile Ser Ser Thr Lys Leu Gln Ala Leu Pro Ser Tyr
225                 230                 235                 240
Gly Leu Glu Ser Ile Gln Arg Leu Ile Ala Thr Ser Ser Tyr Ser Leu
                245                 250                 255
Lys Lys Leu Pro Ser Arg Glu Thr Phe Val Asn Leu Leu Glu Ala Thr
            260                 265                 270
Leu Thr Tyr Pro Ser His Cys Cys Ala Phe Arg Asn Leu Pro Thr Lys
        275                 280                 285
Glu Gln Asn Phe Ser His Ser Ile Ser Glu Asn Phe Ser Lys Gln Cys
    290                 295                 300
Glu Ser Thr Val Arg Lys Val Ser Asn Lys Thr Leu Tyr Ser Ser Met
305                 310                 315                 320
Leu Ala Glu Ser Glu Leu Ser Gly Trp Asp Tyr Glu Tyr Gly Phe Cys
                325                 330                 335
Leu Pro Lys Thr Pro Arg Cys Ala Pro Glu Pro Asp Ala Phe Asn Pro
            340                 345                 350
Cys Glu Asp Ile Met Gly Tyr Asp Phe Leu Arg Val Leu Ile Trp Leu
        355                 360                 365
Ile Asn Ile Leu Ala Ile Met Gly Asn Met Thr Val Leu Phe Val Leu
    370                 375                 380
Leu Thr Ser Arg Tyr Lys Leu Thr Val Pro Arg Phe Leu Met Cys Asn
385                 390                 395                 400
Leu Ser Phe Ala Asp Phe Cys Met Gly Leu Tyr Leu Leu Leu Ile Ala
                405                 410                 415
Ser Val Asp Ser Gln Thr Lys Gly Gln Tyr Tyr Asn His Ala Ile Asp
            420                 425                 430
Trp Gln Thr Gly Ser Gly Cys Ser Thr Ala Gly Phe Phe Thr Val Phe
        435                 440                 445
Ala Ser Glu Leu Ser Val Tyr Thr Leu Thr Val Ile Thr Leu Glu Arg
    450                 455                 460
Trp His Thr Ile Thr Tyr Ala Ile His Leu Asp Gln Lys Leu Arg Leu
465                 470                 475                 480
Arg His Ala Ile Leu Ile Met Leu Gly Gly Trp Leu Phe Ser Ser Leu
                485                 490                 495
Ile Ala Met Leu Pro Leu Val Gly Val Ser Asn Tyr Met Lys Val Ser
            500                 505                 510
Ile Cys Phe Pro Met Asp Val Glu Thr Thr Leu Ser Gln Val Tyr Ile
        515                 520                 525
Leu Thr Ile Leu Ile Leu Asn Val Val Ala Phe Phe Ile Ile Cys Ala
    530                 535                 540
Cys Tyr Ile Lys Ile Tyr Phe Ala Val Arg Asn Pro Glu Leu Met Ala
545                 550                 555                 560
Thr Asn Lys Asp Thr Lys Ile Ala Lys Lys Met Ala Ile Leu Ile Phe
                565                 570                 575
Thr Asp Phe Thr Cys Met Ala Pro Ile Ser Phe Phe Ala Ile Ser Ala
            580                 585                 590
Ala Phe Lys Val Pro Leu Ile Thr Val Thr Asn Ser Lys Val Leu Leu
        595                 600                 605
Val Leu Phe Tyr Pro Ile Asn Ser Cys Ala Asn Pro Phe Leu Tyr Ala
    610                 615                 620
Ile Phe Thr Lys Thr Phe Gln Arg Asp Phe Phe Leu Leu Leu Ser Lys
625                 630                 635                 640
Phe Gly Cys Cys Lys Arg Arg Ala Glu Leu Tyr Arg Arg Lys Asp Phe
                645                 650                 655
Ser Ala Tyr Thr Ser Asn Cys Lys Asn Gly Phe Thr Gly Ser Asn Lys
            660                 665                 670
Pro Ser Gln Ser Thr Leu Lys Leu Ser Thr Leu His Cys Gln Gly Thr
        675                 680                 685
Ala Leu Leu Asp Lys Thr Arg Tyr Thr Glu Cys
    690                 695 
           
           
             
               700 amino acids 
               amino acid 
               linear 
             
             
               protein 
             
             
               unknown 
             
              3
Met Gly Arg Arg Val Pro Ala Leu Arg Gln Leu Leu Val Leu Ala Val
1               5                   10                  15
Leu Leu Leu Lys Pro Ser Gln Leu Gln Ser Arg Glu Leu Ser Gly Ser
            20                  25                  30
Arg Cys Pro Glu Pro Cys Asp Cys Ala Pro Asp Gly Ala Leu Arg Cys
        35                  40                  45
Pro Gly Pro Arg Ala Gly Leu Ala Arg Leu Ser Leu Thr Tyr Leu Pro
    50                  55                  60
Val Lys Val Ile Pro Ser Gln Ala Phe Arg Gly Leu Asn Glu Val Val
65                  70                  75                   80
Lys Ile Glu Ile Ser Gln Ser Asp Ser Leu Glu Arg Ile Glu Ala Asn
                85                  90                  95
Ala Phe Asp Asn Leu Leu Asn Leu Ser Glu Leu Leu Ile Gln Asn Thr
            100                 105                 110
Lys Asn Leu Leu Tyr Ile Glu Pro Gly Ala Phe Thr Asn Leu Pro Arg
        115                 120                 125
Leu Lys Tyr Leu Ser Ile Cys Asn Thr Gly Ile Arg Thr Leu Pro Asp
    130                 135                 140
Val Thr Lys Ile Ser Ser Ser Glu Phe Asn Phe Ile Leu Glu Ile Cys
145                 150                 155                 160
Asp Asn Leu His Ile Thr Thr Ile Pro Gly Asn Ala Phe Gln Gly Met
                165                 170                 175
Asn Asn Glu Ser Val Thr Leu Lys Leu Tyr Gly Asn Gly Phe Glu Glu
            180                 185                 190
Val Gln Ser His Ala Phe Asn Gly Thr Thr Leu Ile Ser Leu Glu Leu
        195                 200                 205
Lys Glu Asn Ile Tyr Leu Glu Lys Met His Ser Gly Ala Phe Gln Gly
    210                 215                 220
Ala Thr Gly Pro Ser Ile Leu Asp Ile Ser Ser Thr Lys Leu Gln Ala
225                 230                 235                 240
Leu Pro Ser His Gly Leu Glu Ser Ile Gln Thr Leu Ile Ala Leu Ser
                245                 250                 255
Ser Tyr Ser Leu Lys Thr Leu Pro Ser Lys Glu Lys Phe Thr Ser Leu
            260                 265                 270
Leu Val Ala Thr Leu Thr Tyr Pro Ser His Cys Cys Ala Phe Arg Asn
        275                 280                 285
Leu Pro Lys Lys Glu Gln Asn Phe Ser Phe Ser Ile Phe Glu Asn Phe
    290                 295                 300
Ser Lys Gln Cys Glu Ser Thr Val Arg Lys Ala Asp Asn Glu Thr Leu
305                 310                 315                 320
Tyr Ser Ala Ile Phe Glu Glu Asn Glu Leu Ser Gly Trp Asp Tyr Asp
                325                 330                 335
Tyr Gly Phe Cys Ser Pro Lys Thr Leu Gln Cys Ala Pro Glu Pro Asp
            340                 345                 350
Ala Phe Asn Pro Cys Glu Asp Ile Met Gly Tyr Ala Phe Leu Arg Val
        355                 360                 365
Leu Ile Trp Leu Ile Asn Ile Leu Ala Ile Phe Gly Asn Leu Thr Val
    370                 375                 380
Leu Phe Val Leu Leu Thr Ser Arg Tyr Lys Leu Thr Val Pro Arg Phe
385                 390                 395                 400
Leu Met Cys Asn Leu Ser Phe Ala Asp Phe Cys Met Gly Leu Tyr Leu
                405                 410                 415
Leu Leu Ile Ala Ser Val Asp Ser Gln Thr Lys Gly Gln Tyr Tyr Asn
            420                 425                 430
His Ala Ile Asp Trp Gln Thr Gly Ser Gly Cys Gly Ala Ala Gly Phe
        435                 440                 445
Phe Thr Val Phe Ala Ser Glu Leu Ser Val Tyr Thr Leu Thr Val Ile
    450                 455                 460
Thr Leu Glu Arg Trp His Thr Ile Thr Tyr Ala Val Gln Leu Asp Gln
465                 470                 475                 480
Lys Leu Arg Leu Arg His Ala Ile Pro Ile Met Leu Gly Gly Trp Leu
                485                 490                 495
Phe Ser Thr Leu Ile Ala Thr Met Pro Leu Val Gly Ile Ser Asn Tyr
            500                 505                 510
Met Lys Val Ser Ile Cys Leu Pro Met Asp Val Glu Ser Thr Leu Ser
        515                 520                 525
Gln Val Tyr Ile Leu Ser Ile Leu Ile Leu Asn Val Val Ala Phe Val
    530                 535                 540
Val Ile Cys Ala Cys Tyr Ile Arg Ile Tyr Phe Ala Val Gln Asn Pro
545                 550                 555                 560
Glu Leu Thr Ala Pro Asn Lys Asp Thr Lys Ile Ala Lys Lys Met Ala
                565                 570                 575
Ile Leu Ile Phe Thr Asp Phe Thr Cys Met Ala Pro Ile Ser Phe Phe
            580                 585                 590
Ala Ile Ser Ala Ala Phe Lys Val Pro Leu Ile Thr Val Thr Asn Ser
        595                 600                 605
Lys Ile Leu Leu Val Leu Phe Tyr Pro Val Asn Ser Cys Ala Asn Pro
    610                 615                 620
Phe Leu Tyr Ala Ile Phe Thr Lys Ala Phe Gln Arg Asp Phe Leu Leu
625                 630                 635                 640
Leu Leu Ser Arg Phe Gly Cys Cys Lys Arg Arg Ala Glu Leu Tyr Arg
                645                 650                 655
Arg Lys Glu Phe Ser Ala Tyr Thr Ser Asn Cys Lys Asn Gly Phe Pro
            660                 665                 670
Gly Ala Ser Lys Pro Ser Gln Ala Thr Leu Lys Leu Ser Thr Val His
        675                 680                 685
Cys Gln Gln Pro Ile Pro Pro Arg Ala Leu Thr His
    690                 695                 700 
           
           
             
               696 amino acids 
               amino acid 
               linear 
             
             
               protein 
             
             
               unknown 
             
              4
Met Arg Arg Arg Ser Leu Ala Leu Arg Leu Leu Leu Ala Leu Leu Leu
1               5                   10                  15
Leu Pro Pro Pro Leu Pro Gln Thr Leu Leu Gly Ala Pro Cys Pro Glu
            20                  25                  30
Pro Cys Ser Cys Arg Pro Asp Gly Ala Leu Arg Cys Pro Gly Pro Arg
        35                  40                  45
Ala Gly Leu Ser Arg Leu Ser Leu Thr Tyr Leu Thr Ile Lys Val Ile
    50                  55                  60
Pro Ser Gln Ala Phe Arg Gly Leu Asn Glu Val Val Lys Ile Glu Ile
65                  70                  75                  80
Ser Gln Ser Asp Ser Leu Glu Lys Ile Glu Ala Asn Ala Phe Asp Asn
                85                  90                  95
Leu Leu Asn Leu Ser Glu Ile Leu Ile Gln Asn Thr Lys Asn Leu Val
            100                 105                 110
Tyr Ile Glu Pro Gly Ala Phe Thr Asn Leu Pro Arg Leu Lys Tyr Leu
        115                 120                 125
Ser Ile Cys Asn Thr Gly Ile Arg Lys Leu Pro Asp Val Thr Lys Ile
    130                 135                 140
Phe Ser Ser Glu Phe Asn Phe Ile Leu Glu Ile Cys Asp Asn Leu His
145                 150                 155                 160
Ile Thr Thr Val Pro Ala Asn Ala Phe Gln Gly Met Asn Asn Glu Ser
                165                 170                 175
Ile Thr Leu Lys Leu Tyr Gly Asn Gly Phe Glu Glu Ile Gln Ser His
            180                 185                 190
Ala Phe Asn Gly Thr Thr Leu Ile Ser Leu Glu Leu Lys Glu Asn Ala
        195                 200                 205
His Leu Lys Lys Met His Asn Asp Ala Phe Arg Gly Ala Arg Gly Pro
    210                 215                 220
Ser Ile Leu Asp Ile Ser Ser Thr Lys Leu Gln Ala Leu Pro Ser Tyr
225                 230                 235                 240
Gly Leu Glu Ser Ile Gln Thr Leu Ile Ala Thr Ser Ser Tyr Ser Leu
                245                 250                 255
Lys Lys Leu Pro Ser Arg Glu Lys Phe Thr Asn Leu Leu Asp Ala Thr
            260                 265                 270
Leu Thr Tyr Pro Ser His Cys Cys Ala Phe Arg Asn Leu Pro Thr Lys
        275                 280                 285
Glu Gln Asn Phe Ser Phe Ser Ile Phe Lys Asn Phe Ser Lys Gln Cys
    290                 295                 300
Glu Ser Thr Ala Arg Arg Pro Asn Asn Glu Thr Leu Tyr Ser Ala Ile
305                 310                 315                 320
Phe Ala Glu Ser Glu Leu Ser Asp Trp Asp Tyr Asp Tyr Gly Phe Cys
                325                 330                 335
Ser Pro Lys Thr Leu Gln Cys Ala Pro Glu Pro Asp Ala Phe Asn Pro
            340                 345                 350
Cys Glu Asp Ile Met Gly Tyr Asp Phe Leu Arg Val Leu Ile Trp Leu
        355                 360                 365
Ile Asn Ile Leu Ala Ile Met Gly Asn Val Thr Val Leu Phe Val Leu
    370                 375                 380
Leu Thr Ser His Tyr Lys Leu Thr Val Pro Arg Phe Leu Met Cys Asn
385                 390                 395                 400
Leu Ser Phe Ala Asp Phe Cys Met Gly Leu Tyr Leu Leu Leu Ile Ala
                405                 410                 415
Ser Val Asp Ala Gln Thr Lys Gly Gln Tyr Tyr Asn His Ala Ile Asp
            420                 425                 430
Trp Gln Thr Gly Asn Gly Cys Ser Val Ala Gly Phe Phe Thr Val Phe
        435                 440                 445
Ala Ser Glu Leu Ser Val Tyr Thr Leu Thr Val Ile Thr Leu Glu Arg
    450                 455                 460
Trp His Thr Ile Thr Tyr Ala Ile Gln Leu Asp Gln Lys Leu Arg Leu
465                 470                 475                 480
Arg His Ala Ile Pro Ile Met Leu Gly Gly Trp Leu Phe Ser Thr Leu
                485                 490                 495
Ile Ala Met Leu Pro Leu Val Gly Val Ser Ser Tyr Met Lys Val Ser
            500                 505                 510
Ile Cys Leu Pro Met Asp Val Glu Thr Thr Leu Ser Gln Val Tyr Ile
        515                 520                 525
Leu Thr Ile Leu Ile Leu Asn Val Val Ala Phe Ile Ile Ile Cys Ala
    530                 535                 540
Cys Tyr Ile Lys Ile Tyr Phe Ala Val Gln Asn Pro Glu Leu Met Ala
545                 550                 555                 560
Thr Asn Lys Asp Thr Lys Ile Ala Lys Lys Met Ala Val Leu Ile Phe
                565                 570                 575
Thr Asp Phe Thr Cys Met Ala Pro Ile Ser Phe Phe Ala Ile Ser Ala
            580                 585                 590
Ala Leu Lys Val Pro Leu Ile Thr Val Thr Asn Ser Lys Val Leu Leu
        595                 600                 605
Val Leu Phe Tyr Pro Val Asn Ser Cys Ala Asn Pro Phe Leu Tyr Ala
    610                 615                 620
Ile Phe Thr Lys Ala Phe Arg Arg Asp Phe Phe Leu Leu Leu Ser Lys
625                 630                 635                 640
Ser Gly Cys Cys Lys His Gln Ala Glu Leu Tyr Arg Arg Lys Asp Phe
                645                 650                 655
Ser Ala Tyr Cys Lys Asn Gly Phe Thr Gly Ser Asn Lys Pro Ser Gln
            660                 665                 670
Ser Thr Leu Lys Leu Thr Thr Leu Gln Cys Gln Tyr Ser Thr Val Met
        675                 680                 685
Asp Lys Thr Cys Tyr Lys Asp Cys
    690                 695 
           
           
             
               764 amino acids 
               amino acid 
               linear 
             
             
               protein 
             
             
               unknown 
             
              5
Met Arg Pro Ala Asp Leu Leu Gln Leu Val Leu Leu Leu Asp Leu Pro
1               5                   10                  15
Arg Asp Leu Gly Gly Met Gly Cys Ser Ser Pro Pro Cys Glu Cys His
            20                  25                  30
Gln Glu Glu Asp Phe Arg Val Thr Cys Lys Asp Ile Gln Arg Ile Pro
        35                  40                  45
Ser Leu Pro Pro Ser Thr Gln Thr Leu Lys Leu Ile Glu Thr His Leu
    50                  55                  60
Arg Thr Ile Pro Ser His Ala Phe Ser Asn Leu Pro Asn Ile Ser Arg
65                  70                  75                  80
Ile Tyr Val Ser Ile Asp Val Thr Leu Gln Gln Leu Glu Ser His Ser
                85                  90                  95
Phe Tyr Asn Leu Ser Lys Val Thr His Ile Glu Ile Arg Asn Thr Arg
            100                 105                 110
Asn Leu Thr Tyr Ile Asp Pro Asp Ala Leu Lys Glu Leu Pro Leu Leu
        115                 120                 125
Lys Phe Leu Gly Ile Phe Asn Thr Gly Leu Lys Met Phe Pro Asp Leu
    130                 135                 140
Thr Lys Val Tyr Ser Thr Asp Ile Phe Phe Ile Leu Glu Ile Thr Asp
145                 150                 155                 160
Asn Pro Tyr Met Thr Ser Ile Pro Val Asn Ala Phe Gln Gly Leu Cys
                165                 170                 175
Asn Glu Thr Leu Thr Leu Lys Leu Tyr Asn Asn Gly Phe Thr Ser Val
            180                 185                 190
Gln Gly Tyr Ala Phe Asn Gly Thr Lys Leu Asp Ala Val Tyr Leu Asn
        195                 200                 205
Lys Asn Lys Tyr Leu Thr Val Ile Tyr Lys Asp Ala Phe Gly Gly Val
    210                 215                 220
Tyr Ser Gly Pro Ser Leu Leu Asp Val Ser Gln Thr Ser Val Thr Ala
225                 230                 235                 240
Leu Pro Ser Lys Gly Leu Glu His Leu Lys Glu Leu Ile Ala Arg Asn
                245                 250                 255
Thr Trp Thr Leu Lys Lys Leu Pro Leu Ser Leu Ser Phe Leu His Leu
            260                 265                 270
Thr Arg Ala Asp Leu Ser Tyr Pro Ser His Cys Cys Ala Phe Lys Asn
        275                 280                 285
Gln Lys Lys Ile Arg Gly Ile Leu Glu Ser Leu Met Cys Asn Glu Ser
    290                 295                 300
Ser Met Gln Ser Leu Arg Gln Arg Lys Ser Val Asn Ala Leu Asn Ser
305                 310                 315                 320
Pro Leu His Gln Glu Tyr Glu Glu Asn Leu Gly Asp Ser Ile Val Gly
                325                 330                 335
Tyr Lys Glu Lys Ser Lys Phe Gln Asp Thr His Asn Asn Ala His Tyr
            340                 345                 350
Tyr Val Phe Phe Glu Glu Gln Glu Asp Glu Ile Ile Gly Phe Gly Gln
        355                 360                 365
Glu Leu Lys Asn Pro Gln Glu Glu Thr Leu Gln Ala Phe Asp Ser His
    370                 375                 380
Tyr Asp Tyr Thr Ile Cys Gly Asp Ser Glu Asp Met Val Cys Thr Pro
385                 390                 395                 400
Lys Ser Asp Glu Phe Asn Pro Cys Glu Asp Ile Met Gly Tyr Lys Phe
                405                 410                 415
Leu Arg Ile Val Val Trp Phe Val Ser Leu Leu Ala Leu Leu Gly Asn
            420                 425                 430
Val Phe Val Leu Leu Ile Leu Leu Thr Ser His Tyr Lys Leu Asn Val
        435                 440                 445
Pro Arg Phe Leu Met Cys Asn Leu Ala Phe Ala Asp Phe Cys Met Gly
    450                 455                 460
Met Tyr Leu Leu Leu Ile Ala Ser Val Asp Leu Tyr Thr His Ser Glu
465                 470                 475                 480
Tyr Tyr Asn His Ala Ile Asp Trp Gln Thr Gly Pro Gly Cys Asn Thr
                485                 490                 495
Ala Gly Phe Phe Thr Val Phe Ala Ser Glu Leu Ser Val Tyr Thr Leu
            500                 505                 510
Thr Val Ile Thr Leu Glu Arg Trp Tyr Ala Ile Thr Phe Ala Met Arg
        515                 520                 525
Leu Asp Arg Lys Met Arg Leu Arg His Ala Cys Ala Ile Met Val Gly
    530                 535                 540
Gly Trp Val Cys Cys Phe Leu Leu Ala Leu Leu Pro Leu Val Gly Ile
545                 550                 555                 560
Ser Ser Tyr Ala Lys Val Ser Ile Cys Leu Pro Met Asp Thr Glu Thr
                565                 570                 575
Pro Leu Ala Leu Ala Tyr Ile Val Phe Val Leu Thr Leu Asn Ile Val
            580                 585                 590
Ala Phe Val Ile Val Cys Cys Cys Tyr Val Lys Ile Tyr Ile Thr Val
        595                 600                 605
Arg Asn Pro Gln Tyr Asn Pro Gly Asp Lys Asp Thr Lys Ile Ala Lys
    610                 615                 620
Arg Met Ala Val Leu Ile Phe Thr Asp Phe Ile Cys Met Ala Pro Ile
625                 630                 635                 640
Ser Phe Tyr Ala Leu Ser Ala Ile Leu Asn Lys Pro Leu Ile Thr Val
                645                 650                 655
Ser Asn Ser Lys Ile Leu Leu Val Leu Phe Tyr Pro Leu Asn Ser Cys
            660                 665                 670
Ala Asn Pro Phe Leu Tyr Ala Ile Phe Thr Lys Glu Phe Gln Arg Asp
        675                 680                 685
Val Phe Ile Leu Leu Ser Lys Phe Gly Ile Cys Lys Arg Gln Ala Gln
    690                 695                 700
Ala Tyr Arg Gly Gln Arg Val Pro Pro Lys Asn Ser Thr Asp Ile Gln
705                 710                 715                 720
Val Gln Lys Val Thr His Glu Met Arg Gln Gly Leu His Asn Met Glu
                725                 730                 735
Asp Val Tyr Glu Leu Ile Glu Lys Ser His Leu Thr Pro Lys Lys Gln
            740                 745                 750
Gly Gln Ile Ser Glu Glu Tyr Met Gln Thr Val Leu
        755                 760 
           
           
             
               692 amino acids 
               amino acid 
               linear 
             
             
               protein 
             
             
               unknown 
             
              6
Met Ala Leu Leu Leu Val Ser Leu Leu Ala Phe Leu Gly Thr Gly Ser
1               5                   10                  15
Gly Cys His His Trp Leu Cys His Cys Ser Asn Arg Val Phe Leu Cys
            20                  25                  30
Gln Asp Ser Lys Val Thr Glu Ile Pro Thr Asp Leu Pro Arg Asn Ala
        35                  40                  45
Ile Glu Leu Arg Phe Val Leu Thr Lys Leu Arg Val Ile Pro Lys Gly
    50                  55                  60
Ser Phe Ala Gly Phe Gly Asp Leu Glu Lys Ile Glu Ile Ser Gln Asn
65                  70                  75                  80
Asp Val Leu Glu Val Ile Glu Ala Asp Val Phe Ser Asn Leu Pro Lys
                85                  90                  95
Leu His Glu Ile Arg Ile Glu Lys Ala Asn Asn Leu Leu Tyr Ile Asn
            100                 105                 110
Pro Glu Ala Phe Gln Asn Leu Pro Ser Leu Arg Tyr Leu Leu Ile Ser
        115                 120                 125
Asn Thr Gly Ile Lys His Leu Pro Ala Val His Lys Ile Gln Ser Leu
    130                 135                 140
Gln Lys Val Leu Leu Asp Ile Gln Asp Asn Ile Asn Ile His Ile Val
145                 150                 155                 160
Ala Arg Asn Ser Phe Met Gly Leu Ser Phe Glu Ser Val Ile Leu Trp
                165                 170                 175
Leu Ser Lys Asn Gly Ile Glu Glu Ile His Asn Cys Ala Phe Asn Gly
            180                 185                 190
Thr Gln Leu Asp Glu Leu Asn Leu Ser Asp Asn Asn Asn Leu Glu Glu
        195                 200                 205
Leu Pro Asn Asp Val Phe Gln Gly Ala Ser Gly Pro Val Ile Leu Asp
    210                 215                 220
Ile Ser Arg Thr Lys Val His Ser Leu Pro Asn His Gly Leu Glu Asn
225                 230                 235                 240
Leu Lys Lys Leu Arg Ala Arg Ser Thr Tyr Arg Leu Lys Lys Leu Pro
                245                 250                 255
Asn Leu Asp Lys Phe Val Thr Leu Met Glu Ala Ser Leu Thr Tyr Pro
            260                 265                 270
Ser His Cys Cys Ala Phe Ala Asn Leu Lys Arg Gln Ile Ser Glu Leu
        275                 280                 285
His Pro Ile Cys Asn Lys Ser Ile Leu Arg Gln Asp Ile Asp Asp Met
    290                 295                 300
Thr Gln Ile Gly Asp Gln Arg Val Ser Leu Ile Asp Asp Glu Pro Ser
305                 310                 315                 320
Tyr Gly Lys Gly Ser Asp Met Met Tyr Asn Glu Phe Asp Tyr Asp Leu
                325                 330                 335
Cys Asn Glu Val Val Asp Val Thr Cys Ser Pro Lys Pro Asp Ala Phe
            340                 345                 350
Asn Pro Cys Glu Asp Ile Met Gly Tyr Asn Ile Leu Arg Val Leu Ile
        355                 360                 365
Trp Phe Ile Ser Ile Leu Ala Ile Thr Gly Asn Thr Thr Val Leu Val
    370                 375                 380
Val Leu Thr Thr Ser Gln Tyr Lys Leu Thr Val Pro Arg Phe Leu Met
385                 390                 395                 400
Cys Asn Leu Ala Phe Ala Asp Leu Cys Ile Gly Ile Tyr Leu Leu Leu
                405                 410                 415
Ile Ala Ser Val Asp Ile His Thr Lys Ser Gln Tyr His Asn Tyr Ala
            420                 425                 430
Ile Asp Trp Gln Thr Gly Ala Gly Cys Asp Ala Ala Gly Phe Phe Thr
        435                 440                 445
Val Phe Ala Ser Glu Leu Ser Val Tyr Thr Leu Thr Ala Ile Thr Leu
    450                 455                 460
Glu Arg Trp His Thr Ile Thr His Ala Met Gln Leu Glu Cys Lys Val
465                 470                 475                 480
Gln Leu Arg His Ala Ala Ser Val Met Val Leu Gly Trp Thr Phe Ala
                485                 490                 495
Phe Ala Ala Ala Leu Phe Pro Ile Phe Gly Ile Ser Ser Tyr Met Lys
            500                 505                 510
Val Ser Ile Cys Leu Pro Met Asp Ile Asp Ser Pro Leu Ser Gln Leu
        515                 520                 525
Tyr Val Met Ala Leu Leu Val Leu Asn Val Leu Ala Phe Val Val Ile
    530                 535                 540
Cys Gly Cys Tyr Thr His Ile Tyr Leu Thr Val Arg Asn Pro Thr Ile
545                 550                 555                 560
Val Ser Ser Ser Ser Asp Thr Lys Ile Ala Lys Arg Met Ala Thr Leu
                565                 570                 575
Ile Phe Thr Asp Phe Leu Cys Met Ala Pro Ile Ser Phe Phe Ala Ile
            580                 585                 590
Ser Ala Ser Leu Lys Val Pro Leu Ile Thr Val Ser Lys Ala Lys Ile
        595                 600                 605
Leu Leu Val Leu Phe Tyr Pro Ile Asn Ser Cys Ala Asn Pro Phe Leu
    610                 615                 620
Tyr Ala Ile Phe Thr Lys Asn Phe Arg Arg Asp Phe Phe Ile Leu Leu
625                 630                 635                 640
Ser Lys Phe Gly Cys Tyr Glu Met Gln Ala Gln Ile Tyr Arg Thr Glu
                645                 650                 655
Thr Ser Ser Ala Thr His Asn Phe His Ala Arg Lys Ser His Cys Ser
            660                 665                 670
Ser Ala Pro Arg Val Thr Asn Ser Tyr Val Leu Val Pro Leu Asn His
        675                 680                 685
Ser Ser Gln Asn
    690 
           
           
             
               636 amino acids 
               amino acid 
               linear 
             
             
               protein 
             
             
               unknown 
             
              7
Met Lys Gln Arg Phe Ser Ala Leu Gln Leu Leu Lys Leu Leu Leu Leu
1               5                   10                  15
Leu Gln Pro Pro Leu Pro Arg Ala Leu Arg Glu Ala Leu Cys Pro Glu
            20                  25                  30
Pro Cys Asn Cys Val Pro Asp Gly Ala Leu Arg Cys Pro Gly Pro Thr
        35                  40                  45
Ala Gly Leu Thr Arg Leu Ser Leu Ala Tyr Leu Pro Val Lys Val Ile
    50                  55                  60
Pro Ser Gln Ala Phe Arg Gly Leu Asn Glu Val Ile Lys Ile Glu Ile
65                  70                  75                  80
Ser Gln Ile Asp Ser Leu Glu Arg Ile Glu Ala Asn Ala Phe Asp Asn
                85                  90                  95
Leu Leu Asn Leu Ser Glu Ile Leu Ile Gln Asn Thr Lys Asn Leu Arg
            100                 105                 110
Tyr Ile Glu Pro Gly Ala Phe Ile Asn Leu Pro Gly Leu Lys Tyr Leu
        115                 120                 125
Ser Ile Cys Asn Thr Gly Ile Arg Lys Phe Pro Asp Val Thr Lys Val
    130                 135                 140
Phe Ser Ser Glu Ser Asn Phe Ile Leu Glu Ile Cys Asp Asn Leu His
145                 150                 155                 160
Ile Thr Thr Ile Pro Gly Asn Ala Phe Gln Gly Met Asn Asn Glu Ser
                165                 170                 175
Val Thr Leu Lys Leu Tyr Gly Asn Gly Phe Glu Glu Val Gln Ser His
            180                 185                 190
Ala Phe Asn Gly Thr Thr Leu Thr Ser Leu Glu Leu Lys Glu Asn Val
        195                 200                 205
His Leu Glu Lys Met His Asn Gly Ala Phe Arg Gly Ala Thr Gly Pro
    210                 215                 220
Lys Thr Gln Asn Phe Ser His Ser Ile Ser Glu Asn Phe Ser Lys Gln
225                 230                 235                 240
Cys Glu Ser Thr Val Arg Lys Val Ser Asn Lys Thr Leu Tyr Ser Ser
                245                 250                 255
Met Leu Ala Glu Ser Glu Leu Ser Gly Trp Asp Tyr Glu Tyr Gly Phe
            260                 265                 270
Cys Leu Pro Lys Thr Pro Arg Cys Ala Pro Glu Pro Asp Ala Phe Asn
        275                 280                 285
Pro Cys Glu Asp Ile Met Gly Tyr Asp Phe Leu Arg Val Leu Ile Trp
    290                 295                 300
Leu Ile Asn Ile Leu Ala Ile Met Gly Asn Met Thr Val Leu Phe Val
305                 310                 315                 320
Leu Leu Thr Ser Arg Tyr Lys Leu Thr Val Pro Arg Phe Leu Met Cys
                325                 330                 335
Asn Leu Ser Phe Ala Asp Phe Cys Met Gly Leu Tyr Leu Leu Leu Ile
            340                 345                 350
Ala Ser Val Asp Ser Gln Thr Lys Gly Gln Tyr Tyr Asn His Ala Ile
        355                 360                 365
Asp Trp Gln Thr Gly Ser Gly Cys Ser Thr Ala Gly Phe Phe Thr Val
    370                 375                 380
Phe Ala Ser Glu Leu Ser Val Tyr Thr Leu Thr Val Ile Thr Leu Glu
385                 390                 395                 400
Arg Trp His Thr Ile Thr Tyr Ala Ile His Leu Asp Gln Lys Leu Arg
                405                 410                 415
Leu Arg His Ala Ile Leu Ile Met Leu Gly Gly Trp Leu Phe Ser Ser
            420                 425                 430
Leu Ile Ala Met Leu Pro Leu Val Gly Val Ser Asn Tyr Met Lys Val
        435                 440                 445
Ser Ile Cys Phe Pro Met Asp Val Glu Thr Thr Leu Ser Gln Val Tyr
    450                 455                 460
Ile Leu Thr Ile Leu Ile Leu Asn Val Val Ala Phe Phe Ile Ile Cys
465                 470                 475                 480
Ala Cys Tyr Ile Lys Ile Tyr Phe Ala Val Arg Asn Pro Glu Leu Met
                485                 490                 495
Ala Thr Asn Lys Asp Thr Lys Ile Ala Lys Lys Met Ala Ile Leu Ile
            500                 505                 510
Phe Thr Asp Phe Thr Cys Met Ala Pro Ile Ser Phe Phe Ala Ile Ser
        515                 520                 525
Ala Ala Phe Lys Val Pro Leu Ile Thr Val Thr Asn Ser Lys Val Leu
    530                 535                 540
Leu Val Leu Phe Tyr Pro Ile Asn Ser Cys Ala Asn Pro Phe Leu Tyr
545                 550                 555                 560
Ala Ile Phe Thr Lys Thr Phe Gln Arg Asp Phe Phe Leu Leu Leu Ser
                565                 570                 575
Lys Phe Gly Cys Cys Lys Arg Arg Ala Glu Leu Tyr Arg Arg Lys Asp
            580                 585                 590
Phe Ser Ala Tyr Thr Ser Asn Cys Lys Asn Gly Phe Thr Gly Ser Asn
        595                 600                 605
Lys Pro Ser Gln Ser Thr Leu Lys Leu Ser Thr Leu His Cys Gln Gly
    610                 615                 620
Thr Ala Leu Leu Asp Lys Thr Arg Tyr Thr Glu Cys
625                 630                 635 
           
           
             
               611 amino acids 
               amino acid 
               linear 
             
             
               protein 
             
             
               unknown 
             
              8
Arg Glu Ala Leu Cys Pro Glu Pro Cys Asn Cys Val Pro Asp Gly Ala
1               5                   10                  15
Leu Arg Cys Pro Gly Pro Thr Ala Gly Leu Thr Arg Leu Ser Leu Ala
            20                  25                  30
Tyr Leu Pro Val Lys Val Ile Pro Ser Gln Ala Phe Arg Gly Leu Asn
        35                  40                  45
Glu Val Ile Lys Ile Glu Ile Ser Gln Ile Asp Ser Leu Glu Arg Ile
    50                  55                  60
Glu Ala Asn Ala Phe Asp Asn Leu Leu Asn Leu Ser Glu Ile Leu Ile
65                  70                  75                  80
Gln Asn Thr Lys Asn Leu Arg Tyr Ile Glu Pro Gly Ala Phe Ile Asn
                85                  90                  95
Leu Pro Gly Leu Lys Tyr Leu Ser Ile Cys Asn Thr Gly Ile Arg Lys
            100                 105                 110
Phe Pro Asp Val Thr Lys Val Phe Ser Ser Glu Ser Asn Phe Ile Leu
        115                 120                 125
Glu Ile Cys Asp Asn Leu His Ile Thr Thr Ile Pro Gly Asn Ala Phe
    130                 135                 140
Gln Gly Met Asn Asn Glu Ser Val Thr Leu Lys Leu Tyr Gly Asn Gly
145                 150                 155                 160
Phe Glu Glu Val Gln Ser His Ala Phe Asn Gly Thr Thr Leu Thr Ser
                165                 170                 175
Leu Glu Leu Lys Glu Asn Val His Leu Glu Lys Met His Asn Gly Ala
            180                 185                 190
Phe Arg Gly Ala Thr Gly Pro Lys Thr Gln Asn Phe Ser His Ser Ile
        195                 200                 205
Ser Glu Asn Phe Ser Lys Gln Cys Glu Ser Thr Val Arg Lys Val Ser
    210                 215                 220
Asn Lys Thr Leu Tyr Ser Ser Met Leu Ala Glu Ser Glu Leu Ser Gly
225                 230                 235                 240
Trp Asp Tyr Glu Tyr Gly Phe Cys Leu Pro Lys Thr Pro Arg Cys Ala
                245                 250                 255
Pro Glu Pro Asp Ala Phe Asn Pro Cys Glu Asp Ile Met Gly Tyr Asp
            260                 265                 270
Phe Leu Arg Val Leu Ile Trp Leu Ile Asn Ile Leu Ala Ile Met Gly
        275                 280                 285
Asn Met Thr Val Leu Phe Val Leu Leu Thr Ser Arg Tyr Lys Leu Thr
    290                 295                 300
Val Pro Arg Phe Leu Met Cys Asn Leu Ser Phe Ala Asp Phe Cys Met
305                 310                 315                 320
Gly Leu Tyr Leu Leu Leu Ile Ala Ser Val Asp Ser Gln Thr Lys Gly
                325                 330                 335
Gln Tyr Tyr Asn His Ala Ile Asp Trp Gln Thr Gly Ser Gly Cys Ser
            340                 345                 350
Thr Ala Gly Phe Phe Thr Val Phe Ala Ser Glu Leu Ser Val Tyr Thr
        355                 360                 365
Leu Thr Val Ile Thr Leu Glu Arg Trp His Thr Ile Thr Tyr Ala Ile
    370                 375                 380
His Leu Asp Gln Lys Leu Arg Leu Arg His Ala Ile Leu Ile Met Leu
385                 390                 395                 400
Gly Gly Trp Leu Phe Ser Ser Leu Ile Ala Met Leu Pro Leu Val Gly
                405                 410                 415
Val Ser Asn Tyr Met Lys Val Ser Ile Cys Phe Pro Met Asp Val Glu
            420                 425                 430
Thr Thr Leu Ser Gln Val Tyr Ile Leu Thr Ile Leu Ile Leu Asn Val
        435                 440                 445
Val Ala Phe Phe Ile Ile Cys Ala Cys Tyr Ile Lys Ile Tyr Phe Ala
    450                 455                 460
Val Arg Asn Pro Glu Leu Met Ala Thr Asn Lys Asp Thr Lys Ile Ala
465                 470                 475                 480
Lys Lys Met Ala Ile Leu Ile Phe Thr Asp Phe Thr Cys Met Ala Pro
                485                 490                 495
Ile Ser Phe Phe Ala Ile Ser Ala Ala Phe Lys Val Pro Leu Ile Thr
            500                 505                 510
Val Thr Asn Ser Lys Val Leu Leu Val Leu Phe Tyr Pro Ile Asn Ser
        515                 520                 525
Cys Ala Asn Pro Phe Leu Tyr Ala Ile Phe Thr Lys Thr Phe Gln Arg
    530                 535                 540
Asp Phe Phe Leu Leu Leu Ser Lys Phe Gly Cys Cys Lys Arg Arg Ala
545                 550                 555                 560
Glu Leu Tyr Arg Arg Lys Asp Phe Ser Ala Tyr Thr Ser Asn Cys Lys
                565                 570                 575
Asn Gly Phe Thr Gly Ser Asn Lys Pro Ser Gln Ser Thr Leu Lys Leu
            580                 585                 590
Ser Thr Leu His Cys Gln Gly Thr Ala Leu Leu Asp Lys Thr Arg Tyr
        595                 600                 605
Thr Glu Cys
    610 
           
           
             
               2022 base pairs 
               nucleic acid 
               double 
               linear 
             
             
               cDNA to mRNA 
             
             
               unknown 
             
             
               CDS 
                1..2022 
             
              9
CGC GAG GCG CTC TGC CCT GAG CCC TGC AAC TGC GTG CCC GAC GGC GCC       48
Arg Glu Ala Leu Cys Pro Glu Pro Cys Asn Cys Val Pro Asp Gly Ala
  1               5                  10                  15
CTG CGC TGC CCC GGC CCC ACG GCC GGT CTC ACT CGA CTA TCA CTT GCC       96
Leu Arg Cys Pro Gly Pro Thr Ala Gly Leu Thr Arg Leu Ser Leu Ala
             20                  25                  30
TAC CTC CCT GTC AAA GTG ATC CCA TCT CAA GCT TTC AGA GGA CTT AAT      144
Tyr Leu Pro Val Lys Val Ile Pro Ser Gln Ala Phe Arg Gly Leu Asn
         35                  40                  45
GAG GTC ATA AAA ATT GAA ATC TCT CAG ATT GAT TCC CTG GAA AGG ATA      192
Glu Val Ile Lys Ile Glu Ile Ser Gln Ile Asp Ser Leu Glu Arg Ile
     50                  55                  60
GAA GCT AAT GCC TTT GAC AAC CTC CTC AAT TTG TCT GAA ATA CTG ATC      240
Glu Ala Asn Ala Phe Asp Asn Leu Leu Asn Leu Ser Glu Ile Leu Ile
 65                  70                  75                  80
CAG AAC ACC AAA AAT CTG AGA TAC ATT GAG CCC GGA GCA TTT ATA AAT      288
Gln Asn Thr Lys Asn Leu Arg Tyr Ile Glu Pro Gly Ala Phe Ile Asn
                 85                  90                  95
CTT CCC GGA TTA AAA TAC TTG AGC ATC TGT AAC ACA GGC ATC AGA AAG      336
Leu Pro Gly Leu Lys Tyr Leu Ser Ile Cys Asn Thr Gly Ile Arg Lys
            100                 105                 110
TTT CCA GAT GTT ACG AAG GTC TTC TCC TCT GAA TCA AAT TTC ATT CTG      384
Phe Pro Asp Val Thr Lys Val Phe Ser Ser Glu Ser Asn Phe Ile Leu
        115                 120                 125
GAA ATT TGT GAT AAC TTA CAC ATA ACC ACC ATA CCA GGA AAT GCT TTT      432
Glu Ile Cys Asp Asn Leu His Ile Thr Thr Ile Pro Gly Asn Ala Phe
    130                 135                 140
CAA GGG ATG AAT AAT GAA TCT GTA ACA CTC AAA CTA TAT GGA AAT GGA      480
Gln Gly Met Asn Asn Glu Ser Val Thr Leu Lys Leu Tyr Gly Asn Gly
145                 150                 155                 160
TTT GAA GAA GTA CAA AGT CAT GCA TTC AAT GGG ACG ACA CTG ACT TCA      528
Phe Glu Glu Val Gln Ser His Ala Phe Asn Gly Thr Thr Leu Thr Ser
                165                 170                 175
CTG GAG CTA AAG GAA AAC GTA CAT CTG GAG AAG ATG CAC AAT GGA GCC      576
Leu Glu Leu Lys Glu Asn Val His Leu Glu Lys Met His Asn Gly Ala
            180                 185                 190
TTC CGT GGG GCC ACA GGG CCG AAA ACC TTG GAT ATT TCT TCC ACC AAA      624
Phe Arg Gly Ala Thr Gly Pro Lys Thr Leu Asp Ile Ser Ser Thr Lys
        195                 200                 205
TTG CAG GCC CTG CCG AGC TAT GGC CTA GAG TCC ATT CAG AGG CTA ATT      672
Leu Gln Ala Leu Pro Ser Tyr Gly Leu Glu Ser Ile Gln Arg Leu Ile
    210                 215                 220
GCC ACG TCA TCC TAT TCT CTA AAA AAA TTG CCA TCA AGA GAA ACA TTT      720
Ala Thr Ser Ser Tyr Ser Leu Lys Lys Leu Pro Ser Arg Glu Thr Phe
225                 230                 235                 240
GTC AAT CTC CTG GAG GCC ACG TTG ACT TAC CCC AGC CAC TGC TGT GCT      768
Val Asn Leu Leu Glu Ala Thr Leu Thr Tyr Pro Ser His Cys Cys Ala
                245                 250                 255
TTT AGA AAC TTG CCA ACA AAA GAA CAG AAT TTT TCA CAT TCC ATT TCT      816
Phe Arg Asn Leu Pro Thr Lys Glu Gln Asn Phe Ser His Ser Ile Ser
            260                 265                 270
GAA AAC TTT TCC AAA CAA TGT GAA AGC ACA GTA AGG AAA GTG AGT AAC      864
Glu Asn Phe Ser Lys Gln Cys Glu Ser Thr Val Arg Lys Val Ser Asn
        275                 280                 285
AAA ACA CTT TAT TCT TCC ATG CTT GCT GAG AGT GAA CTG AGT GGC TGG      912
Lys Thr Leu Tyr Ser Ser Met Leu Ala Glu Ser Glu Leu Ser Gly Trp
    290                 295                 300
GAC TAT GAA TAT GGT TTC TGC TTA CCC AAG ACA CCC CGA TGT GCT CCT      960
Asp Tyr Glu Tyr Gly Phe Cys Leu Pro Lys Thr Pro Arg Cys Ala Pro
305                 310                 315                 320
GAA CCA GAT GCT TTT AAT CCC TGT GAA GAC ATT ATG GGC TAT GAC TTC     1008
Glu Pro Asp Ala Phe Asn Pro Cys Glu Asp Ile Met Gly Tyr Asp Phe
                325                 330                 335
CTT AGG GTC CTG ATT TGG CTG ATT AAT ATT CTA GCC ATC ATG GGA AAC     1056
Leu Arg Val Leu Ile Trp Leu Ile Asn Ile Leu Ala Ile Met Gly Asn
            340                 345                 350
ATG ACT GTT CTT TTT GTT CTC CTG ACA AGT CGT TAC AAA CTT ACA GTG     1104
Met Thr Val Leu Phe Val Leu Leu Thr Ser Arg Tyr Lys Leu Thr Val
        355                 360                 365
CCT CGT TTT CTC ATG TGC AAT CTC TCC TTT GCA GAC TTT TGC ATG GGG     1152
Pro Arg Phe Leu Met Cys Asn Leu Ser Phe Ala Asp Phe Cys Met Gly
    370                 375                 380
CTC TAT CTG CTG CTC ATA GCC TCA GTT GAT TCC CAA ACC AAG GGC CAG     1200
Leu Tyr Leu Leu Leu Ile Ala Ser Val Asp Ser Gln Thr Lys Gly Gln
385                 390                 395                 400
TAC TAT AAC CAT GCC ATA GAC TGG CAG ACA GGG AGT GGG TGC AGC ACT     1248
Tyr Tyr Asn His Ala Ile Asp Trp Gln Thr Gly Ser Gly Cys Ser Thr
                405                 410                 415
GCT GGC TTT TTC ACT GTA TTC GCA AGT GAA CTT TCT GTC TAC ACC CTC     1296
Ala Gly Phe Phe Thr Val Phe Ala Ser Glu Leu Ser Val Tyr Thr Leu
            420                 425                 430
ACC GTC ATC ACT CTA GAA AGA TGG CAC ACC ATC ACC TAT GCT ATT CAC     1344
Thr Val Ile Thr Leu Glu Arg Trp His Thr Ile Thr Tyr Ala Ile His
        435                 440                 445
CTG GAC CAA AAG CTG CGA TTA AGA CAT GCC ATT CTG ATT ATG CTT GGA     1392
Leu Asp Gln Lys Leu Arg Leu Arg His Ala Ile Leu Ile Met Leu Gly
    450                 455                 460
GGA TGG CTC TTT TCT TCT CTA ATT GCT ATG TTG CCC CTT GTC GGT GTC     1440
Gly Trp Leu Phe Ser Ser Leu Ile Ala Met Leu Pro Leu Val Gly Val
465                 470                 475                 480
AGC AAT TAC ATG AAG GTC AGT ATT TGC TTC CCC ATG GAT GTG GAA ACC     1488
Ser Asn Tyr Met Lys Val Ser Ile Cys Phe Pro Met Asp Val Glu Thr
                485                 490                 495
ACT CTC TCA CAA GTC TAT ATA TTA ACC ATC CTG ATT CTC AAT GTG GTG     1536
Thr Leu Ser Gln Val Tyr Ile Leu Thr Ile Leu Ile Leu Asn Val Val
            500                 505                 510
GCC TTC TTC ATA ATT TGT GCT TGC TAC ATT AAA ATT TAT TTT GCA GTT     1584
Ala Phe Phe Ile Ile Cys Ala Cys Tyr Ile Lys Ile Tyr Phe Ala Val
        515                 520                 525
CGA AAC CCA GAA TTA ATG GCT ACC AAT AAA GAT ACA AAG ATT GCT AAG     1632
Arg Asn Pro Glu Leu Met Ala Thr Asn Lys Asp Thr Lys Ile Ala Lys
    530                 535                 540
AAA ATG GCA ATC CTC ATC TTC ACC GAT TTC ACC TGC ATG GCA CCT ATC     1680
Lys Met Ala Ile Leu Ile Phe Thr Asp Phe Thr Cys Met Ala Pro Ile
545                 550                 555                 560
TCT TTT TTT GCC ATC TCA GCT GCC TTC AAA GTA CCT CTT ATC ACA GTA     1728
Ser Phe Phe Ala Ile Ser Ala Ala Phe Lys Val Pro Leu Ile Thr Val
                565                 570                 575
ACC AAC TCT AAA GTT TTA CTG GTT CTT TTT TAT CCC ATC AAT TCT TGT     1776
Thr Asn Ser Lys Val Leu Leu Val Leu Phe Tyr Pro Ile Asn Ser Cys
            580                 585                 590
GCC AAT CCA TTT CTG TAT GCA ATA TTC ACT AAG ACA TTC CAA AGA GAT     1824
Ala Asn Pro Phe Leu Tyr Ala Ile Phe Thr Lys Thr Phe Gln Arg Asp
        595                 600                 605
TTC TTT CTT TTG CTG AGC AAA TTT GGC TGC TGT AAA CGT CGG GCT GAA     1872
Phe Phe Leu Leu Leu Ser Lys Phe Gly Cys Cys Lys Arg Arg Ala Glu
    610                 615                 620
CTT TAT AGA AGG AAA GAT TTT TCA GCT TAC ACC TCC AAC TGC AAA AAT     1920
Leu Tyr Arg Arg Lys Asp Phe Ser Ala Tyr Thr Ser Asn Cys Lys Asn
625                 630                 635                 640
GGC TTC ACT GGA TCA AAT AAG CCT TCT CAA TCC ACC TTG AAG TTG TCC     1968
Gly Phe Thr Gly Ser Asn Lys Pro Ser Gln Ser Thr Leu Lys Leu Ser
                645                 650                 655
ACA TTG CAC TGT CAA GGT ACA GCT CTC CTA GAC AAG ACT CGC TAC ACA     2016
Thr Leu His Cys Gln Gly Thr Ala Leu Leu Asp Lys Thr Arg Tyr Thr
            660                 665                 670
GAG TGT                                                             2022
Glu Cys 
           
           
             
               674 amino acids 
               amino acid 
               linear 
             
             
               protein 
             
             
               unknown 
             
              10
Arg Glu Ala Leu Cys Pro Glu Pro Cys Asn Cys Val Pro Asp Gly Ala
  1               5                  10                  15
Leu Arg Cys Pro Gly Pro Thr Ala Gly Leu Thr Arg Leu Ser Leu Ala
             20                  25                  30
Tyr Leu Pro Val Lys Val Ile Pro Ser Gln Ala Phe Arg Gly Leu Asn
         35                  40                  45
Glu Val Ile Lys Ile Glu Ile Ser Gln Ile Asp Ser Leu Glu Arg Ile
     50                  55                  60
Glu Ala Asn Ala Phe Asp Asn Leu Leu Asn Leu Ser Glu Ile Leu Ile
 65                  70                  75                  80
Gln Asn Thr Lys Asn Leu Arg Tyr Ile Glu Pro Gly Ala Phe Ile Asn
                 85                  90                  95
Leu Pro Gly Leu Lys Tyr Leu Ser Ile Cys Asn Thr Gly Ile Arg Lys
            100                 105                 110
Phe Pro Asp Val Thr Lys Val Phe Ser Ser Glu Ser Asn Phe Ile Leu
        115                 120                 125
Glu Ile Cys Asp Asn Leu His Ile Thr Thr Ile Pro Gly Asn Ala Phe
    130                 135                 140
Gln Gly Met Asn Asn Glu Ser Val Thr Leu Lys Leu Tyr Gly Asn Gly
145                 150                 155                 160
Phe Glu Glu Val Gln Ser His Ala Phe Asn Gly Thr Thr Leu Thr Ser
                165                 170                 175
Leu Glu Leu Lys Glu Asn Val His Leu Glu Lys Met His Asn Gly Ala
            180                 185                 190
Phe Arg Gly Ala Thr Gly Pro Lys Thr Leu Asp Ile Ser Ser Thr Lys
        195                 200                 205
Leu Gln Ala Leu Pro Ser Tyr Gly Leu Glu Ser Ile Gln Arg Leu Ile
    210                 215                 220
Ala Thr Ser Ser Tyr Ser Leu Lys Lys Leu Pro Ser Arg Glu Thr Phe
225                 230                 235                 240
Val Asn Leu Leu Glu Ala Thr Leu Thr Tyr Pro Ser His Cys Cys Ala
                245                 250                 255
Phe Arg Asn Leu Pro Thr Lys Glu Gln Asn Phe Ser His Ser Ile Ser
            260                 265                 270
Glu Asn Phe Ser Lys Gln Cys Glu Ser Thr Val Arg Lys Val Ser Asn
        275                 280                 285
Lys Thr Leu Tyr Ser Ser Met Leu Ala Glu Ser Glu Leu Ser Gly Trp
    290                 295                 300
Asp Tyr Glu Tyr Gly Phe Cys Leu Pro Lys Thr Pro Arg Cys Ala Pro
305                 310                 315                 320
Glu Pro Asp Ala Phe Asn Pro Cys Glu Asp Ile Met Gly Tyr Asp Phe
                325                 330                 335
Leu Arg Val Leu Ile Trp Leu Ile Asn Ile Leu Ala Ile Met Gly Asn
            340                 345                 350
Met Thr Val Leu Phe Val Leu Leu Thr Ser Arg Tyr Lys Leu Thr Val
        355                 360                 365
Pro Arg Phe Leu Met Cys Asn Leu Ser Phe Ala Asp Phe Cys Met Gly
    370                 375                 380
Leu Tyr Leu Leu Leu Ile Ala Ser Val Asp Ser Gln Thr Lys Gly Gln
385                 390                 395                 400
Tyr Tyr Asn His Ala Ile Asp Trp Gln Thr Gly Ser Gly Cys Ser Thr
                405                 410                 415
Ala Gly Phe Phe Thr Val Phe Ala Ser Glu Leu Ser Val Tyr Thr Leu
            420                 425                 430
Thr Val Ile Thr Leu Glu Arg Trp His Thr Ile Thr Tyr Ala Ile His
        435                 440                 445
Leu Asp Gln Lys Leu Arg Leu Arg His Ala Ile Leu Ile Met Leu Gly
    450                 455                 460
Gly Trp Leu Phe Ser Ser Leu Ile Ala Met Leu Pro Leu Val Gly Val
465                 470                 475                 480
Ser Asn Tyr Met Lys Val Ser Ile Cys Phe Pro Met Asp Val Glu Thr
                485                 490                 495
Thr Leu Ser Gln Val Tyr Ile Leu Thr Ile Leu Ile Leu Asn Val Val
            500                 505                 510
Ala Phe Phe Ile Ile Cys Ala Cys Tyr Ile Lys Ile Tyr Phe Ala Val
        515                 520                 525
Arg Asn Pro Glu Leu Met Ala Thr Asn Lys Asp Thr Lys Ile Ala Lys
    530                 535                 540
Lys Met Ala Ile Leu Ile Phe Thr Asp Phe Thr Cys Met Ala Pro Ile
545                 550                 555                 560
Ser Phe Phe Ala Ile Ser Ala Ala Phe Lys Val Pro Leu Ile Thr Val
                565                 570                 575
Thr Asn Ser Lys Val Leu Leu Val Leu Phe Tyr Pro Ile Asn Ser Cys
            580                 585                 590
Ala Asn Pro Phe Leu Tyr Ala Ile Phe Thr Lys Thr Phe Gln Arg Asp
        595                 600                 605
Phe Phe Leu Leu Leu Ser Lys Phe Gly Cys Cys Lys Arg Arg Ala Glu
    610                 615                 620
Leu Tyr Arg Arg Lys Asp Phe Ser Ala Tyr Thr Ser Asn Cys Lys Asn
625                 630                 635                 640
Gly Phe Thr Gly Ser Asn Lys Pro Ser Gln Ser Thr Leu Lys Leu Ser
                645                 650                 655
Thr Leu His Cys Gln Gly Thr Ala Leu Leu Asp Lys Thr Arg Tyr Thr
            660                 665                 670
Glu Cys